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81. ABSTRACT
The number of diabetic patients is an increasing 
worldwide health care problem. Approximately 
one third will eventually develop the diabetic 
kidney complication, diabetic nephropathy. 
Microalbuminuria is the most widely used mark-
er but at the time of diagnosis there are already 
advanced lesions in the kidney fi ltration appa-
ratus, the glomeruli. Nephrin is an important 
molecule in the glomeruli and it forms part of 
the fi ltration barrier, through which the primary 
urine is fi ltered. The expression of nephrin shows 
characteristic changes in diabetes and in other ac-
quired proteinuric diseases. 
Hypercholesterolemia is one of the known 
risk factors for kidney damage and a constant 
fi nding in kidney diseases. The present study 
investigated the causal relationship of hyperc-
holesterolemia and proteinuria, and the effect of 
hypercholesterolemia on glomerular damage and 
on nephrin expression in the mouse. The study 
found that hypercholesterolemia was a prerequi-
site for proteinuria and that nephrin expression 
was diminished both at the mRNA and protein 
levels. Increased lipid peroxidation was involved 
in the pathogenic process in this model.
In the development of diabetic nephropa-
thy, nephrin expression increases initially just 
before albuminuria starts and diminishes at the 
stage of overt albuminuria. In the present study, 
type 1 diabetic patients with or without neph-
ropathy were studied for the presence of urinary 
proteins detectable with nephrin antisera. First, 
urine from one third of the patients showed 
proteins that reacted with nephrin antisera. The 
presence of these protein fragments was not asso-
ciated with clinical variables. Second, the 75 kDa 
protein turned out to be the most specifi c for 
nephrin. In two separate type 1 diabetic patient 
cohorts the occurrence of this 75 kDa nephrin 
was signifi cantly lower in patients with more se-
vere nephropathy, and the occurrence was high-
est in the diabetic patients with no clinical signs 
of nephropathy. Of type 1 diabetic patients 73 
were followed for an average of 7.8 years for the 
progression of nephropathy. 20% of progressors 
and 42% of non-progressors showed 75 kDa ne-
phrin in urine at baseline (p=0.23). Further stud-
ies are needed to evaluate whether this protein 
may serve as a marker for progression of diabetic 
nephropathy. In this cohort, healthy controls 
were negative for the presence of urinary proteins 
reacting with nephrin antiserum.
Nondiabetic fi rst-degree relatives of T2DM 
patients have an almost threefold increased life-
time risk of diabetes compared to the background 
population. Type 2 diabetes is often preceded by 
a stage characterized by alterations in glucose me-
tabolism. First-degree relatives of type 2 diabetic 
patients are more insulin resistant, and they may 
also show other signs of the metabolic syndrome, 
such as central adiposity, hypertension, glucose 
intolerance, hypercoagulability, microalbuminu-
ria, and dyslipidemia. In the present study urine 
samples from the offspring of type 2 diabetic 
patients were investigated for the presence of 
proteins reacting with nephrin antiserum. Of the 
offspring, 27% showed a 100 kDa urinary pro-
tein in the urine, while healthy controls were all 
negative. The offspring were further divided into 
strongly positive, weakly positive and negative 
groups according to the presence of this protein. 
The strongly positive offspring were signifi cantly 
9more insulin resistant compared to the negative 
offspring and their nonoxidative glucose disposal 
was lower. It is possible that insulin resistance 
and diabetes cause changes in podocyte metabo-
lism and in nephrin expression, which is refl ected 
in urine.
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2.1. The kidney; fi ltration function and   
 structure
The main functions of the kidneys are secretion 
of metabolic end products, maintenance of cor-
rect fl uid, electrolyte, and acid-base balance of the 
body and participation in production of crucial 
substances like the vitamin D and erythropoietin 
(Guyton, 1991). One kidney (Figure 2.1) con-
tains an estimated 500 000 nephrons which are 
the basic functional units forming urine. A ne-
phron (Figure 2.2) is composed of a glomerulus 
(the capillary bundle), through which fl uid is fi l-
tered from blood and primary urine is produced, 
and a long tubule in which the primary urine is 
transformed into fi nal urine. The tubule can be 
divided anatomically and functionally into dis-
tinct parts with specifi c roles in water and elec-
trolyte balance, pH regulation, reabsorption of 
fi ltered substances and secretion of metabolic end 
products. From tubules urine fl ows through the 
collecting duct system to the renal pelvis, and fi -
nally via ureters to the bladder. The outer zone of 
the kidney, the cortex, contains all the glomeruli 
and the inner zone, the medulla, contains parts 
of the tubules and the fi nal parts of the collect-
ing ducts. Blood enters the glomerulus via the 
afferent arteriole and then leaves via the efferent 
arteriole, which directs the blood then through 
the peritubular capillary network surrounding 
the entire tubular system. The tubular epithelial 
cells are in addition to reabsorbing valuable sub-
stances from the tubular lumen also capable of 
actively secreting substances from the blood into 
the urine (O’Callaghan and Brenner, 2000). 
Figure 2.1 Figure 2.2
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An estimated 180 liters of primary urine is 
fi ltered each day through the selectively perme-
able glomerular fi ltration barrier into the Bow-
man’s capsule (the urinary space) surrounding 
the glomerulus (Figure 2.3). The fi ltration bar-
rier itself comprises capillary endothelial cells, 
glomerular basement membrane (GBM) and 
visceral epithelial cells, called podocytes. The 
capillary endothelial cells have abundant 70-100 
nm openings (fenestrations), which are aligned 
with negatively charged glycoproteins and lipids 
(Tisher and Madsen, 1991). This unique po-
rosity allows free contact of components of the 
blood circulation with the underlying GBM, al-
though favoring fi ltration of cationic molecules. 
The negatively charged, 300 nm-thick, GBM is 
composed mainly of type IV collagen and lam-
inin, as well as heparan sulphate proteoglycans 
(agrin and perlecan), fi bronectin, and nidogen 
(Miner, 1999; Timpl, 1989). The podocytes are 
facing directly the urinary space. They have long 
projections from which the primary and second-
ary foot processes arise, and attach to the urinary 
side of the glomerular basement membrane. The 
foot processes from neighbouring podocytes in-
terdigitate and it is proposed that they form form 
35-45 nm zipper-like fi ltration slit diaphragms 
separating foot processes from each other (Rode-
wald and Karnovsky, 1974; Tryggvason, 1999). 
This arrangement allows free passage of small 
molecules through the slit while preventing leak-
age of large molecules into the primary urine. 
It has been suggested that the slits may be par-
tially elastic and that the slit width may increase 
with pulsating intraglomerular pressure (Kriz 
et al., 1996; Yu et al., 1997). Electron micro-
scopic (EM) studies have shown that the width 
of the slit might vary even between 20-50 nm 
(Ohno et al., 1992) although different fi xation 
methods may alter the dimensions measurable 
by EM (Furukawa et al., 1991). The fi ltration 
barrier functions both as a size-selective and a 
charge-selective sieve. The glomerulus also con-
tains mesangial cells, which provide a scaffold to 
support the capillary loops and have contractile 
and phagocytic properties (Hawkins et al., 1990; 
Pfeilschifter et al., 1993).
Figure 2.3
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2.2. Nephrin as an interacting component of  
 the podocyte proteome
2.2.1. Nephrin
The glomerular fi ltration barrier is affected in 
numerous primary and secondary kidney dis-
eases resulting in leakage of albumin and larger 
plasma proteins into the urine with generalized 
oedema and nephrotic syndrome as the fi nal con-
sequence. Congenital nephrotic syndrome of the 
Finnish type (CNF) is an autosomal, recessive 
disorder, characterized by massive proteinuria 
in utero and nephrosis at birth (Hallman et al., 
1956; Norio et al., 1964). This syndrome is seen 
in 1:10000 to 1:8000 newborns in Finland (Hol-
mberg et al., 1996) and serves as a model disease 
for podocyte-specifi c proteinuria. The typical 
clinical symptoms include severe hypoproteine-
mia due to massive loss of circulating proteins 
into the urine most likely due to a fi ltration slit 
defect. Other symptoms include edema, hyperli-
pidemia, and susceptibility for thromboembolic 
complications and for bacterial infections. The 
patients show overt proteinuria of intrauterine 
onset, which is associated with enlargement of 
the placenta and high alpha-fetoprotein levels in 
amnionic fl uid and in maternal serum (Holm-
berg et al., 1996). The characteristic pathologic 
fi ndings are fusion of the podocyte foot proc-
esses (foot process effacement), dilation of the 
proximal tubules, mesangial hypercellularity, and 
thickening of the GBM (Hallman et al., 1956; 
Huttunen et al., 1980; Ljungberg et al., 1993). 
Using positional cloning Kestilä et al. were 
able to identify the nephrin gene (NPHS1) mu-
tated in CNF (Kestila et al., 1998). This gene 
is located in the long arm of chromosome nine-
teen in locus 13.1 and contains 29 exons (Kestila 
et al., 1994; Mannikko et al., 1995). The gene 
product, nephrin, is a 1241-residue transmem-
brane protein belonging to the immunoglobulin 
super family (Figure 2.4 and 2.5). Two muta-
tions account for most Finnish patients and 
lead to synthesis of a truncated form of nephrin; 
frameshift deletion in exon 2 (Finn major) and 
nonsense mutation in exon 26 (Finn minor). In 
other countries point mutations in the nephrin 
gene cause sporadic cases closely resembling 
CNF (Beltcheva et al., 2001; Lenkkeri et al., 
1999). Although CNF is a recessive disorder, 
fetal carriers of the nephrin mutation show fu-
sion of the podocyte foot processes, temporary 
proteinuria, and a false positive alpha-fetoprotein 
test (Patrakka et al., 2002a). Later on one func-
tional allele is enough and carriers show normal 
kidney function. Nephrin-defi cient mouse mod-
els strengthen the crucial role of nephrin in the 
glomerular fi ltration function by expressing heavy 
proteinuria (Putaala et al., 2001) (Hamano et al., 
2002; Rantanen et al., 2002). Interestingly, one 
third of the foot processes were fused in electron 
micrographs and there was over 60% decrease 
of nephrin-specifi c mRNA level in glomeruli of 
asymptomatic heterozygous nephrin-defi cient 
mice (Rantanen et al., 2002). 
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Nephrin is expressed in the islets of Lang-
erhans in the pancreas (Palmen et al., 2001; 
Putaala et al., 2001). Positive protein staining has 
been found in the pancreatic beta cells (Palmen 
et al., 2001), and recently in islet microendothe-
lium (Zanone et al., 2005). The exact function 
of pancreatic nephrin is still not known, but it 
may serve as a structural protein in islet micro-
endothelium (Zanone et al., 2005). Moreover, 
controversial data on whether nephrin is truly 
expressed in the pancreas do exist suggesting 
that nephrin has not major signifi cance outside 
the kidney (Kuusniemi et al., 2004). Nephrin is 
expressed also in distinct locations in the mouse 
brain during brain development (Putaala et al., 
2001), in the Sertoli cells of mouse testis (Liu et 
al., 2001), and in rat spleen (Ahola et al., 1999). 
In the kidney nephrin is specifi cally located at 
the slit diaphragm (Holthofer et al., 1999; Ruot-
salainen et al., 1999) and its strands contribute to 
the protein scaffold of the fi ltration slit as seen in 
electron tomography (Wartiovaara et al., 2004). 
Spliced nephrin (nephrin α) has been found at 
the mRNA level in both the rat and human kid-
ney (Ahola et al., 1999; Holthofer et al., 1999; 
Luimula et al., 2000a) as well as in the pancreas 
(Palmen et al., 2001). Nephrin α lacks the whole 
amino acid sequence spanning the transmem-
brane domain encoded by exon 24 in the human 
and thus could represent a soluble form of the 
protein. The eight extracellular Ig-like domains of 
nephrin are of type C2 that is typically found in 
proteins participating in cell-cell (Brummendorf 
and Rathjen, 1995; Chothia and Jones, 1997) 
or cell-matrix interactions (Fahrig et al., 1987). 
Nephrin has three free cysteine residues which 
are suggested to form disulfi de bridges between 
different nephrin molecules so that homophilic 
interactions between different nephrin molecules 
over the slit are possible (Kestila et al., 1998; Try-
ggvason, 1999). Nephrin was shown to form a 
homophilic interaction with nephrin and a het-
erophilic interaction with NEPH1 (Gerke et al., 
2003) (Barletta et al., 2003; Liu et al., 2003). 
The homophilic interaction of extracellular ne-
phrin was of high affi nity and was promoted by 
calcium ions (Khoshnoodi et al., 2003). The 90-
kDa NEPH1 is a protein with weak homology 
Figure 2.4
14
and structural similarity to nephrin. The lack of 
NEPH1 leads to prenatal lethality with proteinu-
ria in Neph1 -/- mice (Donoviel et al., 2001). The 
calculated molecular mass of nephrin is 132.5 
kDa, while in sodium dodecyl sulfate-polyacry-
lamide gel electrophoresis (SDS-PAGE) nephrin 
runs as a 185-200 kDa protein doublet suggest-
ing posttranslational modifi cations (Ahola et al., 
1999; Topham et al., 1999). In the extracellular 
part of human nephrin there are ten potential 
sites for N-glycosylation (Kestila et al., 1998) 
and it has been shown that mouse nephrin is N-
glycosylated (Holzman et al., 1999) and that N-
glycosylation of nephrin is critical for its proper 
folding and localization in the plasma membrane 
(Yan et al., 2002). Glycosylation is needed also 
for proper interaction with NEPH1 (Gerke et 
al., 2003). Nephrin carries seven potential at-
tachment sites for heparan sulfate (Kestila et al., 
1998).
Nephrin also contains a fi bronectin type 
III-like domain in the extracellular part near the 
transmembrane region and an intracellular C-
terminal part. Nephrin has signaling functions 
enabled by the nine tyrosines of the intracellular 
domain, some of which are phosphorylated dur-
ing ligand binding as well as endogenously (Ver-
ma et al., 2003). Oligomerized nephrin is associ-
ated with signalling microdomains, lipid rafts, in 
a cholesterol dependent manner (Simons et al., 
2001). In vivo injection of antibodies against po-
docyte-specifi c 9-O-acetylated GD3 ganglioside, 
which is an important component of lipid rafts, 
leads to morphological changes of the fi ltration 
slits resembling foot process effacement. In this 
model nephrin dislocated to the apical pole of 
the narrowed fi ltration slits and was tyrosine 
phosphorylated (Simons et al., 2001). Further-
more, clustering of extracellular domain of ne-
phrin by nephrin antibodies in a cell line leads 
to disruption of cell-cell contacts (Khoshnoodi 
et al., 2003) and to phosphorylation of nephrin 
by Src family kinases (Lahdenperä et al., 2003). 
Similarly intravenous injection of the nephrin-
specifi c monoclonal antibody 5-1-6 induced 
massive proteinuria in rats (Orikasa et al., 1988) 
and decreased nephrin expression (Kawachi et 
al., 2000). Phosphorylated nephrin is able to 
bind p85 regulatory subunit of phosphoinositide 
3-OH kinase (PI3K) and activate by phosphor-
ylation the PI3K target protein, serine-threonine 
kinase AKT (Huber et al., 2003a). This leads to 
phosphorylation of downstream molecules, one 
of which is the proapoptotic Bcl-2 family mem-
ber Bad. Phosphorylation of Bad prevents detach-
ment-induced apoptosis and safeguards podocyte 
viability (Huber et al., 2003a). However, Foster 
et al. suggested that vascular endothelial growth 
factor (VEGF) treatment caused nephrin phos-
phorylation together with decrease in AKT-sig-
naling (Foster et al., 2005). Glycoprotein VEGF 
is a key survival factor for vascular endothelium 
(Ferrara, 2002). Down-regulation or neutraliza-
tion of circulating VEGF caused proteinuria with 
endothelial cell detachment, podocyte changes, 
and reduction in nephrin expression (Sugimoto 
et al., 2003). The infl ammatory cytokines inter-
leukin-1β and tumor necrosis factor-α are able 
to up-regulate nephrin expression in podocytes 
in vitro and this phenomenon involves activity 
of an unknown protein kinase (Huwiler et al., 
2003). The protein kinase C (PKC) pathway 





2.2.2. Proteins of the slit diaphragm area 
CD2 adaptor protein (CD2AP), initially found 
to be associated with the T-lymphocyte molecule 
CD2, is also present at the slit membrane level in 
podocytes and is linked to the intracellular part 
of nephrin via its C-terminal domain (Palmen 
et al., 2002; Shih et al., 2001). The N-terminal 
part of CD2AP binds to p85 and potentiates the 
nephrin-induced AKT activation (Huber et al., 
2003a). CD2AP-knockout mice have defects in 
the foot processes of podocytes and hyperplasia 
of the mesangial cells with extracellular matrix 
depositions (Shih et al., 1999). Although CD2AP 
knockout mice develop nephrotic syndrome sim-
ilar to CNF, the symptoms develop later, at the 
age of 3-4 weeks. This suggests that the function 
of CD2AP might be compensated for at some 
stage by other proteins (Shih et al., 1999). Kid-
neys from CD2AP -/- mice initially exhibited 
normal nephrin localization, but with aging the 
foot processes became effaced and the nephrin 
disappeared (Li et al., 2000). CD2AP is con-
nected directly or indirectly to F-actin (Welsch 
et al., 2001), and nephrin in the slits is linked to 
the actin cytoskeleton, possibly through CD2AP 
or other intermediary linker proteins (Yuan et al., 
2002a). These may include densin (Ahola et al., 
2003), IQGAP1 (Liu et al., 2005), p120 catenin, 
P-cadherin, and CASK (Lehtonen et al., 2004), 
which have very recently been found being di-
rectly or indirectly linked to nephrin (Figure 
2.5). 
Another important protein at the slit area 
is podocin, which is mutated in autosomal reces-
sive familiar focal segmental glomerulosclerosis, 
sporadic focal segmental glomerulosclerosis, and 
in some CNF patients in whom nephrin muta-
tions are not found (Boute et al., 2000; Karle et 
al., 2002; Koziell et al., 2002; Roselli et al., 2002; 
Tsukaguchi et al., 2000). Podocin is a hairpin-
like integral membrane protein belonging to the 
stomatin family and it is also accumulated in an 
oligomerized form in lipid rafts, localizing at 
the insertion site of the slit diaphragm (Roselli 
et al., 2002; Schwarz et al., 2001). Pull-down 
experiments and co-immunoprecipitations have 
revealed that podocin associates via its C-termi-
nal domain with CD2AP and nephrin, and may 
serve as a scaffolding protein in the organization 
of the slit diaphragm complex (Huber et al., 2001; 
Schwarz et al., 2001). Podocin also increased 
the ability of nephrin to activate mitogen-acti-
vated protein kinase cascades in the embryonic 
kidney 293T cell system by recruiting nephrin 
into lipid rafts (Huber et al., 2001; Huber et al., 
2003b). Mutations in C-terminal podocin causes 
retention of both podocin and nephrin in endo-
plasmic reticulum showing no staining of these 
proteins at the plasma membrane in transfected 
human embryonic kidney cells (Nishibori et al., 
2004). Depending on the mutation podocin ei-
ther does not leave the endoplasmic reticulum or 
localize in lipid rafts on the plasma membrane 
and is consequently unable to potentiate nephrin 
signaling (Huber et al., 2003b). Knocking down 
podocin expression in a podocyte cell line by 
mRNA interference decreased nephrin expres-
sion by 70% and altered nephrin localization 
from the membrane surface to the nuclear area 
(Fan et al., 2004). Podocin-defi cient mice also 
show antenatal proteinuria, fusion of foot proc-
esses and massive mesangial sclerosis with vastly 
reduced nephrin expression (Roselli et al., 2004). 
Podocin interacts with the C-terminal domain of 
NEPH1 and with two other NEPH-family pro-
teins, NEPH2 and NEPH3, which are similar to 
nephrin (Ihalmo et al., 2003; Sellin et al., 2003). 
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Defective action of podocin might have a role in 
the development of secondary focal segmental 
glomerulosclerosis observed in various diseases 
such as diabetic nephropathy, HIV nephropathy 
and morbid obesity. 
The membrane protein ZO-1, namely its 
isoform lacking motif-alpha, is expressed in the 
cytoplasmic surface of the slit (Kurihara et al., 
1992a; Kurihara et al., 1992b). ZO-1 is not at-
tached to nephrin and the same holds true for 
the transmembrane protein occludin (Holthofer 
et al., 1999). ZO-1 has a different staining pat-
tern compared to nephrin (Kawachi et al., 2000) 
and it is normally found at the cytosolic side of 
tight junctions where it interacts with occludin 
and with the actin cytoskeleton (Balda and Mat-
ter, 2000). Early in podocyte development tight 
junctions are found in place of the slit membranes 
and therefore it was suggested that the mature slit 
membrane is actually a modifi ed tight junction 
(Schnabel et al., 1990). Supporting this view, Ka-
wachi et al. reported down-regulation of ZO-1 in 
proteinuric diseases (Kawachi et al., 1997). Other 
studies, however, failed to identify any changes in 
ZO-1 expression during proteinuria (Bains et al., 
1997; Rantanen et al., 2002; Yuan et al., 2002b). 
In addition, other proteins characteristic for tight 
junctions have not been found from the slit area. 
Instead, members of adherens junctions, α-, β-, 
and γ-catenin as well as P-cadherin that can also 
associate with ZO-1 were observed (Reiser et al., 
2000). Since P-cadherin defi cient mice and hu-
mans with a mutation in P-cadherin gene show 
no kidney phenotype it may not have signifi -
cance for the glomerular fi ltration (Dahl et al., 
2002; Radice et al., 1997; Sprecher et al., 2001). 
Another member of the cadherin super family, 
FAT, has been localized to the slit area co-localiz-
ing with ZO-1 and nephrin but its function still 
remains unknown (Inoue et al., 2001).
Mutations in a cytosolic actin-fi lament 
cross-linking protein, α-actinin-4, have also been 
shown to cause another form of proteinuric dis-
ease, the autosomal dominant familial focal seg-
mental glomerulosclerosis (Kaplan et al., 2000). 
Most likely this protein is one of the links for 
the slit diaphragm proteins to the actin cytoskel-
eton for fi nal functional effects: changing rapidly 
the shape of podocytes from the well organized 
orderly foot processes to the fl attening found in 
proteinuric states. An intact submembranous 
actin cytoskeleton appears to be indispensable 
for maintaining podocyte architecture. Endlich 
et al. have shown that mechanical stress induces 
reorganization of the actin cytoskeleton in po-
docytes by a calcium and Rho kinase dependent 
mechanism (Endlich et al., 2001). Saleem et al. 
also showed that nephrin and podocin expression 
was altered in a podocyte cell line after treatment 
with cytochalasin D, an agent known to de-po-
lymerize actin stress fi bers (Saleem et al., 2002).
2.2.3. Apical side of podocytes 
The apical membrane of foot processes consti-
tutes another functional unit. Podocalyxin is a 
highly glycosylated integral membrane protein 
which is thought to contribute to the mainte-
nance of the negative charge in the podocyte 
plasma membrane and thus keep the fi ltration 
pores open (Dekan et al., 1991; Kerjaschki et 
al., 1984). It is mainly distributed on the apical 
surface of glomerular podocytes and contributes 
directly to the stability of foot processes, be-
cause a genetic knockout resulted in immature 
glomeruli with fl attened embryonic podocytes 
(Doyonnas et al., 2001). GLEPP1 is a receptor 
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tyrosine phosphatase present also on the apical 
side of the podocytes and it is thought to regu-
late the glomerular fi ltration through an effect on 
podocyte structure and function (Thomas et al., 
1994; Wharram et al., 2000). GLEPP1 knock-
out mice showed reduced nephrin expression, re-
duced glomerular fi ltration rate, fewer foot proc-
esses, but no detectable increase in proteinuria 
(Wharram et al., 2000).
2.2.4. Basal side of podocytes 
The sole of the foot process is linked to the 
GBM by dystroglycan (Regele et al., 2000), 
α3β1 integrin (Kerjaschki et al., 1989), podo-
planin (Breiteneder-Geleff et al., 1997; Matsui 
et al., 1998), and megalin (Kerjaschki and Far-
quhar, 1983). α3β1 integrin is important for 
podocyte maturation (Kreidberg et al., 1996) 
but in glomerular diseases it comprises a static 
bond between podocytes and the GBM, and 
its expression is relatively stable. α3β1 integrin 
associates with the podocyte actin cytoskeleton 
through paxillin, talin, vinculin or α-actinin 
(Drenckhahn and Franke, 1988; Otey et al., 
1993). Dystroglycan complex associates with the 
actin cytoskeleton through utrophin (Raats et al., 
2000). Both the dystroglycan complex and α3β1 
integrin attach to laminin and agrin of the GBM 
(Kerjaschki, 2001). Megalin belongs to the LDL-
receptor family and serves as an endocytic recep-
tor for lipoproteins (Kerjaschki et al., 1997). 
2.3. Puromycin aminonucleoside nephrosis 
The aminonucleoside of puromycin has been 
used to induce experimental proteinuric neph-
ropathy. PAN has shown to be morphologically 
and functionally a useful experimental model for 
human minimal change nephropathy (Vernier et 
al., 1959). Minimal change nephropathy mani-
fests usually at childhood and its typical features 
are proteinuria, hypoalbuminemia, hyperlipi-
demia, and occasionally haematuria (Glassock et 
al., 1991). Pathologic lesions include thickening 
of the capillary wall, subepithelial and intramem-
branous immune complex deposits together with 
disruption of podocyte foot process structure 
(Glassock et al., 1991). PAN may be induced 
with a single puromycin injection leading to pro-
teinuria starting around day 3, peaking at day 10, 
and resolving by day 28 after injection (Ryan and 
Karnovsky, 1975). Injection of puromycin ami-
nonucleoside leads to proteinuria in rats, which 
is characterized by detachment of the podocyte 
foot processes and GBM alterations (Caulfi eld et 
al., 1976). The number of foot processes is re-
duced, the foot processes are fused and the slit 
diaphragms are altered, even lost and replaced by 
occluding-type junctions (Caulfi eld et al., 1976; 
Kurihara et al., 1992b). The tubuli show dilation 
(Ryan and Karnovsky, 1975; Vernier et al., 1959) 
and fi nally the ruptured epithelium detaches 
from the GBM and allows direct contact of the 
GBM with the urinary space (Messina et al., 
1987). Mice are generally resistant to the effects 
of puromycin, but proteinuria can be induced in 
mice with adriamycin possibly by a toxic effect 
mediated by the immune system (Amore et al., 
1996; Chen et al., 1995). In some mouse strains 
repeated puromycin injections produce proteinu-
ria (Pierce and Nakane, 1969). Both adriamycin 
and puromycin nephrosis mimic closely human 
minimal change nephropathy, but these toxins 
act most likely at different levels fi nally exerting 
their effects on protein synthesis. Adriamycin 
acts at the DNA level while puromycin acts on 
ribosomes (Whiteside et al., 1989).
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Ahola et al. fi rst showed that nephrin mRNA 
expression was reduced already at day 3 after 
PAN induction (Ahola et al., 1999), thus before 
proteinuria appeared. Kawachi et al. found that 
nephrin mRNA expression was reduced already 
two hours after puromycin injection by 51.2% 
when proteinuria was not yet present (Kawachi 
et al., 2000). Nephrin expression still decreased 
to a level of 20% of normal at day 10, as shown 
both in mRNA and protein levels (Luimula et 
al., 2000b). The nephrin staining pattern was al-
tered from the basolateral area towards the more 
apical area in EM (Luimula et al., 2000b) and 
from a linear to a coarse granular appearance in 
immunofl uorescence (Kawachi et al., 2000). Ne-
phrin expression has also been found to be com-
parable to normal in areas where slits are well 
preserved, but lower in areas of foot process ef-
facement (Lee et al., 2004). Luimula et al. found 
urinary nephrin of molecular size of 166 kDa 
in the most proteinuric urine samples (Luimula 
et al., 2000a). Podocin was down-regulated in 
PAN similar to nephrin (Luimula et al., 2002) 
although differing results also exist suggesting 
that pathogenic factors may cause disconnection 
of nephrin and podocin and result in an altered 
expression pattern (Kawachi et al., 2003). Saleem 
et al. reported that puromycin caused similar 
granular redistribution of both nephrin and actin 
in a podocyte cell line suggesting disruption of 
the actin-linked protein complex (Saleem et al., 
2002). Expressional changes of other podocyte 
proteins in PAN are reviewed by Pavenstädt et al. 
(Pavenstadt et al., 2003). 
Podocytes are particularly susceptible to 
toxic injury by oxidants. Overproduction of reac-
tive oxygen species (ROS) through the xanthine 
oxidase pathway has been reported in PAN (Dia-
mond et al., 1986). In vitro studies have shown 
that puromycin exerts an impact on rat glomeru-
lar epithelial cells by generation of active oxygen 
(Kawaguchi et al., 1992; Ricardo et al., 1994). 
Several studies have shown that antioxidants re-
duce proteinuria in PAN and inhibit foot process 
effacement (Diamond et al., 1986; Ricardo et al., 
1994; Thakur et al., 1988). The major pheno-
types in antioxidant-defective mouse overpro-
ducing ROS are podocyte injury and glomerulo-
sclerosis (Binder et al., 1999). In PAN, podocyte 
depletion and glomerulosclerosis have a direct 
relationship (Kim et al., 2001). Probucol, a mol-
ecule that prevents lipid peroxidation, normal-
izes nephrin expression and prevents proteinuria 
in PAN (Luimula et al., 2000b). Administration 
of retinoid acid (vitamin A) to PAN rats amel-
iorated proteinuria and induced nephrin expres-
sion, but the exact pathway of this phenomenon 
is not yet known (Suzuki et al., 2003). 
2.4. Apolipoprotein E 
ApoE is a 34 kDa serum protein that mediates 
extracellular cholesterol transport and regulates 
multiple metabolic pathways. It is involved in 
the pathogenesis of atherosclerosis and Alzhe-
imer’s disease (Mahley and Huang, 1999). ApoE 
is a constituent of very low density lipoprotein 
synthesized by the liver, of intestinally synthe-
sized chylomicrons, and of a subfraction of the 
high-density lipoproteins (Mahley, 1986). ApoE 
mediates high-affi nity binding of ApoE-con-
taining lipoprotein particles to the low density 
lipoprotein (LDL) receptor and is thus, among 
its other functions, responsible for the cellular 
uptake of these particles (Hui et al., 1981). The 
ApoE-knockout (ApoE-KO) mouse line was 
originally created using homologous recombina-
tion (Plump et al., 1992). These mice show high 
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cholesterol levels even when on low fat diet and 
have extensive atherosclerotic lesions at the age 
of ten weeks (Plump et al., 1992; Zhang et al., 
1992). Elevated levels of very low and interme-
diate density lipoproteins are mainly responsi-
ble for the hypercholesterolemia in this model 
(Plump et al., 1992). Although the ApoE and 
total cholesterol levels in mice and men are dif-
ferent, the mouse ApoE knockout model has 
provided an invaluable insight into the roles of 
lipids and disease.
ApoE plays a role in the pathogenesis and 
progression of a variety of renal diseases, as well 
as in their atherosclerotic complications (Libe-
ropoulos et al., 2004). Abnormal lipoprotein 
metabolism accelerates atherosclerosis and pre-
disposes to the development of global glomeru-
losclerosis in patients with renal disease (Keane et 
al., 1988). For example increased Lipoprotein(a) 
level may contribute to accelerated atheroscle-
rosis in ESRD patients (Milionis et al., 1999; 
Siamopoulos et al., 1995), whereas the ApoE 
polymorphism has been shown to infl uence the 
Lipoprotein(a) levels in nonuremic subjects (de 
Knijff et al., 1991). The polymorphisms of ApoE 
have been suggested to act as major determinants 
of plasma lipid levels of uremic patients (Libe-
ropoulos et al., 2004). Certain mutations of the 
ApoE gene are associated with the unique and 
rare disorder, the lipoprotein glomerulopathy, 
which is characterized by nephrotic-range pro-
teinuria without systemic manifestations (Saito et 
al., 2002). The histological features include pres-
ence of lipoprotein thrombi in capillary lumina 
of affected glomeruli, foam cells, vascular chang-
es, and segmental sclerosis with periglomerular 
fi brosis in advanced stages of the disease (Saito 
et al., 1999). In normal glomeruli mesangial cells 
are the major expressors of ApoE and it has been 
speculated that ApoE may act as an autocrine 
regulator of mesangial and glomerular functions 
(Liberopoulos et al., 2004).
2.5. Type 1 diabetes 
Finland has the world’s highest incidence for 
type 1 diabetes mellitus (T1DM) being approxi-
mately 50 new annual cases per 100 000 chil-
dren under the age of 15 years (Reunanen, 2004; 
Tuomilehto et al., 1999). The number of T1DM 
patients in Finland is now around 30 000 (Re-
unanen, 2004). The disease usually starts at an 
early age and is characterized by hyperglycemia 
caused by insulin defi ciency leading to symptoms 
like weight loss, thirst and polyuria. Insulin-pro-
ducing beta cells in the pancreas are slowly de-
stroyed by an autoimmune mechanism launched 
by (polygenic) genetic and environmental factors. 
The autoimmune pre-diabetic process is charac-
terized by T-cell infi ltrations around the islets 
of Langerhans and fi nally inside the islets (Bot-
tazzo et al., 1985; Gepts, 1965; Hanninen et al., 
1992; Itoh et al., 1993). The patients carry sev-
eral autoantibodies to beta cell autoantigens like 
glutamic acid decarboxylase (GAD65, GAD67), 
insulin and protein tyrosine phosphatase-related 
IA-2 molecule, and these antibodies are used to 
diagnose the pre-diabetic stage (Baekkeskov et 
al., 1990; Knip, 2002; Lan et al., 1996). HLA 
genotyping has been used also in evaluating 
subjects at risk for T1DM (Kupila et al., 2001). 
Although more than 90% of the patients with 
T1DM carry the predisposing HLA-DQ8 and/
or –DQ2 alleles, only a minority of the geneti-
cally susceptible individuals progress to clinical 
disease (Kimpimaki et al., 2001b). There is evi-
dence that environmental factors such as entero-
virus infections (Hiltunen et al., 1997; Hyoty et 
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al., 1995), short-term breastfeeding (Kimpimaki 
et al., 2001a), and early induction of cow’s milk-
based infant formulas (Vaarala et al., 1999) may 
predispose genetically susceptible children to 
T1DM. Several intervention studies aimed at the 
prevention of T1DM are underway. The disease 
was untreatable until the discovery of insulin by 
Banting and Best in 1922 but although insulin 
replacement therapies are nowadays very good 
they are not completely able to mimic the physi-
ological production of insulin.
2.6. Type 2 diabetes
The incidence of type 2 diabetes mellitus 
(T2DM) has increased during the last decades 
all over the world. The World Health Organi-
zation has estimated that there will be over 300 
million diabetic patients in the world by the year 
2025. In Finland there are now around 190 000 
T2DM patients and the estimated number will 
be around 400 000 by the year 2030 (Reunanen, 
2004). T2DM is a heterogeneous metabolic 
disorder characterized by defects both in insu-
lin secretion and in insulin action (DeFronzo, 
1988). T2DM can be present sub-clinically for 
many years (Harris et al., 1992) because symp-
toms of hyperglycemia manifest slowly and often 
the fi rst symptoms are secondary, like infections. 
For many T2DM patients, insulin resistance is 
marked and forms part of the metabolic syn-
drome, which also includes central adiposity, 
hypertension, glucose intolerance, hypercoagu-
lation tendency, microalbuminuria, and dysli-
pidemia (Alberti and Zimmet, 1998). Develop-
ment of T2DM is, to some extent, predictable. 
Family history of diabetes and obesity are potent 
risk factors amplifi ed by increasing age. In ad-
dition, both fasting hyperinsulinemia and fast-
ing plasma glucose concentration independently 
indicate an enhanced risk of developing the dis-
ease (Haffner et al., 1990; Haffner et al., 1992). 
Insulin resistance and diabetes are not equiva-
lent end points, and insulin resistance and beta 
cell dysfunction independently predict diabetes 
(Weyer et al., 2001). Several studies in different 
populations have identifi ed anthropometrical 
and metabolic characteristics that increase the 
likelihood that a person with initially normal 
glucose tolerance will progress to diabetes over a 
specifi c period of time (Hanley et al., 2003; Har-
ris et al., 1987; Zimmet and Whitehouse, 1978). 
Hanley et al. showed in a combined analysis of 
three prospective studies that the presence of one 
or more components of the metabolic syndrome, 
namely, hyperinsulinemia, dyslipidemia, hyper-
tension, and glucose intolerance, predicted the 
emergence of diabetes over 8 years of follow-up 
(Hanley et al., 2003).
Concordance rates for T2DM are high-
er in monozygotic twins who share 100% of 
their genes, than in dizygotic twins who share 
less genes (Barnett et al., 1981; Newman et al., 
1987). However, no consistent inheritance pat-
tern has emerged, with some studies suggesting 
a major gene effect while others are more in 
keeping with polygenic inheritance. Nondiabetic 
fi rst-degree relatives of T2DM patients have an 
almost threefold increased lifetime risk of diabe-
tes in comparison to the background population. 
Insulin resistance is an early metabolic feature 
of nondiabetic fi rst-degree relatives of T2DM 
patients (Eriksson et al., 1989) and also shows 
familial clustering in keeping with an underly-
ing genetic predisposition (Lillioja et al., 1987). 
Maturity-onset diabetes of the young (MODY), 
a comparatively rare type of diabetes, is a mono-
genic disease and inherited as autosomal domi-
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nant trait. MODY is characterized by beta cell 
dysfunction and young age at diagnosis, usually 
less than 25 years, leading to early-onset T2DM. 
There are at least six genes implicated in the 
pathogenesis of different forms of the disease 
(Frayling et al., 2001; Pearson et al., 2001). 
2.7. Diabetic nephropathy 
General pathologic complications caused by 
both T1DM and T2DM are usually divided 
into macrovascular and microvascular. The mi-
crovascular complications impair the function 
of small arteries partially by non-enzymatic gly-
cosylation and the most common target organs 
are the kidneys, the peripheral nerves, and the 
eyes. Approximately one third of T1DM patients 
and one fi fth of T2DM patients will eventually 
develop a diabetic kidney complication, dia-
betic nephropathy (DN). It is characterized by 
hypertension, persistent proteinuria, decline in 
renal function fi nally leading to renal failure and 
uremia. The fi rst clinical sign of nephropathy is 
microalbuminuria caused by leakage of albumin 
to urine through the impaired glomerular fi ltra-
tion barrier. This albumin is detected by routine 
laboratory methods such as radioimmunoassay. 
Microalbuminuria is defi ned as a 24-h urinary 
albumin excretion rate (AER) of 30–300 mg in 
two of three consecutive 24-h urine collections 
and macroalbuminuria as AER >300 mg/24 h. 
From spot urine sample microalbuminuria may 
be determined by normalizing the excretion of 
albumin to creatinine. Microalbuminuric cut-
off-points for albumin/creatinine ratios are 3.5 
mg/mmol for women and 2.5 mg/mmol for men 
(Viberti et al., 1994). 
The fi rst histopathologic lesions of DN 
include enlarged glomeruli (hypertrophy, hyper-
plasia and glomerulomegaly), which is associated 
with increased glomerular fi ltration rate (GFR) 
(Mauer et al., 1984). At the microalbuminu-
ric stage the glomerular basement membrane is 
thickened and there is mesangial matrix expan-
sion, which may be accompanied by mild mesang-
ial hypercellularity (Osterby et al., 1983). Overt 
glomerular matrix expansion (glomerulosclerosis) 
manifests as two basic patterns: diffuse glomeru-
losclerosis and nodular glomerulosclerosis. These 
two patterns often are present together in a bi-
opsy specimen (Jennette, 2004). The nodular le-
sions of diabetic glomerulosclerosis were fi rst de-
scribed by Kimmelstiel and Wilson and are thus 
called Kimmelstiel-Wilson nodules (Kimmelstiel 
and Wilson, 1936). The nodules are often focal 
and segmental, although sometimes biopsies may 
show diffuse global nodularity. Glomerular hy-
alinosis is a common feature of diabetic glomeru-
losclerosis. Diabetic glomerulosclerosis is found 
in both type 1 and type 2 diabetes. In the latter it 
is somewhat more heterogeneous in appearance, 
in part because of concurrent changes caused by 
hypertension and aging (Bertani et al., 1996; 
Gambara et al., 1993). Atherosclerosis typically 
accompanies diabetic glomerulosclerosis. The 
earliest tubular change is thickening of the tu-
bular basement membrane that is analogous to 
thickening of the GBM. With advancing disease, 
tubules become atrophic and the interstitium de-
velops fi brosis and chronic infl ammation. In EM 
the typical fi ndings are thickening of the GBM, 
mesangial matrix expansion and hyalinosis (Jen-
nette, 2004). 
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2.8. Factors affecting the pathogenesis of   
 diabetic nephropathy
The landmark study that established the value 
of intensive blood glucose control to prevent 
the microvascular complications of T1DM was 
the Diabetes Control and Complications study 
(Anonymous, 1993). A few years later the UK 
Prospective Diabetes Study (UKPDS) fulfi lled 
the same role for T2DM (Anonymous, 1998a, 
b). At the time of diagnosis of T1DM an in-
crease in AER can be observed, which may be-
come normal when glycaemic control improves 
(Mogensen, 1971). Also in non-diabetic subjects 
the prevalence of microalbuminuria increases 
with decreasing glucose tolerance (Collins et al., 
1989). There are at least four main hypotheses 
that are proposed to explain how hyperglycemia 
causes diabetic complications: increased ad-
vanced glycation end-product (AGE) formation, 
increased polyol pathway fl ux, activation of PKC 
isoforms, and increased hexosamine pathway 
fl ux (Brownlee, 2001). It appears that intracel-
lular hyperglycemia leads to formation of reac-
tive, intracellular dicarbonyls, which react with 
amino groups of intracellular and extracellular 
proteins to form AGEs (Brownlee, 2001). The 
AGEs alter the structure and function of the in-
tracellular proteins, and the extracellular matrix 
components modifi ed by AGE precursors have 
altered function leading to altered cell to cell in-
teraction. The plasma proteins modifi ed by AGE 
precursors bind to AGE receptors on various cell 
types and induce receptor-mediated production 
of ROS leading to pathologic changes in gene ex-
pression and to vascular damage. Chronic hyper-
glycemia causes an increased fl ux of glucose via 
the polyol pathway and leads to accumulation of 
intracellular sorbitol. This may increase osmotic 
stress, induce activation of PKC or increase the 
intracellular oxidative stress in the cells, but the 
effects may be species, site, and tissue dependent 
(Brownlee, 2001). In vivo studies of inhibition 
of the polyol pathway have yielded inconsist-
ent results. Activation of PKC isoforms by the 
lipid second messenger diacylglycerol (DAG) 
stimulates extracellular matrix production, ex-
pression of growth factors, and alters the func-
tion of vascular cells (Koya et al., 1997; Koya 
and King, 1998). Shunting of excess intracellu-
lar glucose into the hexosamine pathway might 
cause manifestation of diabetic complications 
possibly through transforming growth factor-β 
(TGF-β)-dependent increased mesangial matrix 
production (Kolm-Litty et al., 1998). Activation 
of the hexosamine pathway by hyperglycemia 
may result in alterations of gene expression and 
protein function. Recently, it was found that 
overproduction of superoxide by the mitochon-
drial electron-transport chain would activate all 
the four hyperglycemia-induced pathways and 
would thus be a common denominator for these 
four mechanisms (Du et al., 2000; Nishikawa et 
al., 2000).
Hypertension is a key player in the patho-
genesis of DN, because intraglomerular pressure 
can increase protein fi ltration and fi nally cause 
mesangial expansion (Hostetter et al., 1982). In-
creased blood pressure is one of the key symp-
toms of DN, but it has also been thought that it 
may be secondary to the condition. Studies have 
shown that blood pressure lowering drugs, like 
ACE inhibitors, are able to postpone the devel-
opment of DN in T1DM (Anonymous, 1996; 
Lewis et al., 1993; Mogensen et al., 1995). The 
same effect has been shown with angiotensin II 
type 1 receptor blockers on development of DN 
in T2DM patients (Brenner et al., 2001; Lewis 
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et al., 2001; Parving et al., 2001). Interestingly, 
in an experimental model AGE-RAGE-medi-
ated ROS generation activated TGF-β-Smad 
signaling and subsequently induced mesangial 
cell hypertrophy and fi bronectin synthesis by au-
tocrine angiotensin II production in mesangial 
cells (Fukami et al., 2004).
Hyperlipidemia is one of the typical features 
of DN (Groop et al., 1996) but whether hyper-
lipidemia causes renal injury is not known. Ab-
normalities in lipid metabolism have been found 
already in microalbuminuric diabetic patients 
(Jensen et al., 1988; Tarnow et al., 1996). In a 
rat nephrectomy model of kidney injury a lipid-
lowering agent clofi bric acid reduced proteinuria 
(Kasiske et al., 1988) while cholesterol-lowering 
drug, lovastatin, did the same in diabetic rats (In-
man et al., 1999). DN in T1DM has also been 
associated with genetic factors (Seaquist et al., 
1989), smoking (Muhlhauser et al., 1986), high 
protein intake (Pedrini et al., 1996), and male 
gender (Seliger et al., 2001).
2.9. Nephrin in diabetic nephropathy
Streptozotocin (STZ) injection into rats causes 
rapid destruction of insulin-producing pancreat-
ic beta cells leading to the phenotype of T1DM 
(Junod et al., 1967). Non-obese diabetic mice 
(NOD mice) spontaneously develop T1DM at 
the age of 3 to 6 months after T cell -mediated 
destruction of beta cells (Tisch et al., 1993). In 
these models it takes from four to eight weeks af-
ter the onset of diabetes to develop the fi rst signs 
of nephropathy, enlargement of the glomeruli 
and albuminuria, if the blood glucose levels are 
not controlled well enough with insulin (Doi et 
al., 1990; O’Donnell et al., 1988). Aaltonen et al. 
showed that glomerular nephrin expression was 
increased by 50% in the STZ rats 4 weeks after 
induction of diabetes and a two-fold increase was 
present in 3 weeks old NOD mice even thought 
these mice did not demonstrate diabetes at that 
stage yet (Aaltonen et al., 2001). Whole-sized 
nephrin was found in the urine of the STZ-rats 
from 4 to 6 weeks after induction. Bonnet at al 
used STZ in spontaneously hypertensive rats and 
at 32 weeks the animals showed advanced DN 
together with clear reduction in both glomerular 
nephrin mRNA and protein levels (Bonnet et al., 
2001). Very similar results have been observed 
in several other studies with an initial increase 
in nephrin expression after induction of diabe-
tes followed by a later decrease in advanced DN 
(Forbes, 2002). 
ACE inhibitors and angiotensin-receptor 
antagonists, which modulate the renin-angi-
otensin system (RAS), are known to reduce pro-
teinuria (Lewis et al., 1993; Lewis et al., 2001). 
It has now been shown in several studies that 
these agents are able to normalize the decreased 
nephrin expression in experimental models of 
diabetes both at the mRNA and protein levels 
(Bonnet et al., 2001; Kelly et al., 2002). In a sim-
ilar model the ACE inhibitor ramipril and an-
giotensin-receptor antagonist valsartan were able 
to normalize the structural alterations like podo-
cyte foot process broadening and thickening of 
the GBM (Mifsud et al., 2001). RAS modifying 
agents are also able to modify the specifi c ZO-1 
redistribution (Macconi et al., 2000). Podocytes 
express both type 1 and type 2 angiotensin II re-
ceptors and it has been shown that angiotensin II 
causes an increase in cyclic AMP and rearrange-
ment of the actin cytoskeleton in podocytes, 
which is normalized by blocking simultaneously 
both receptors (Sharma et al., 1998). Stimula-
tion of cultured podocytes with angiotensin II 
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or glycated albumin has been shown to cause a 
reduction in nephrin expression (Doublier et al., 
2003). This was mediated through RAGE for 
glycated albumin and through cytoskeletal rear-
rangement for angiotensin II (Doublier et al., 
2003). Controversial studies exist on treatment 
of diabetic rats with aminoguanidine, a blocker of 
AGE formation. One study showed no effect of 
aminoguanidine on nephrin expression in a STZ 
model, although it reduced proteinuria (Kelly et 
al., 2002), while another study showed normali-
zation of nephrin expression in a similar model 
and even an additive effect with the ACE inhibi-
tor, perindopril (Davis et al., 2004). Davis also 
showed that the vasopeptidase inhibitor, omap-
atrilat, was able to restore reduced nephrin ex-
pression in a similar model (Davis et al., 2003b). 
It is not surprising since vasopeptidase inhibitors 
simultaneously inhibit both ACE and neutral en-
dopeptidase, a zinc dependent metallopeptidase. 
This leads to decreased levels of vasoconstrictor 
effector molecules such as angiotensin II as well 
as an increase in the levels of vasodilatory agents 
such as atrial natriuretic peptide and bradykinin 
(Fournie-Zaluski et al., 1994). It seems that the 
changes in nephrin expression are not only due 
to a reduction in blood pressure, since calcium 
channel blockers that reduced blood pressure 
equally effectively compared to angiotensin-re-
ceptor antagonist valsartan in a STZ model, had 
no effect on decreased nephrin expression (Davis 
et al., 2003a). Blanco et al. showed in a Zucker 
rat model that mimics T2DM that the ACE in-
hibitor quinapril increased nephrin expression 
while the calcium channel blocker diltiazem 
did not when compared to untreated diabetic 
animals (Blanco et al., 2005). Unfortunately this 
study did not compare the results to nondiabetic 
animals, so whether nephrin expression is altered 
per se in T2DM experimental model compared 
to nondiabetic animals remains unknown.
Langham et al. investigated renal biopsies 
from T2DM patients with proteinuria who had 
been randomized to receive the ACE inhibitor 
perindopril or placebo for two years. Nephrin 
mRNA was reduced in diabetic patients com-
pared to healthy controls by 62% while the levels 
of perindopril treated patients were similar to the 
levels of the controls (Langham et al., 2002). Dou-
blier et al. found a reduction in nephrin protein 
levels both in T1DM and T2DM patients with 
nephrotic syndrome (Doublier et al., 2003). They 
found a profound reduction in nephrin staining 
already in patients with microalbuminuria and 
that the staining pattern was changed to granular 
from the normal linear. Koop et al. showed that 
nephrin protein expression was reduced in biop-
sies of DN patients, while podocin and podoca-
lyxin staining was comparable to that of normal 
controls (Koop et al., 2003). In this study they 
found inverse correlation between nephrin pro-
tein levels and mean width of the podocyte foot 
processes but no correlation between nephrin 
and serum creatinine. Toyoda et al. showed an 
inverse correlation between glomerular nephrin 
mRNA levels and proteinuria in T2DM patients 
with DN (Toyoda et al., 2004). Benigni et al. 
reported that in diabetic nephropathy of T2DM 
extracellular nephrin staining was reduced while 
staining with nephrin antibody against the intra-
cellular domain was normal suggesting a possible 
diabetes-associated nephrin splicing (Benigni et 
al., 2004). None of the human studies has as-
sessed nephrin expression in normoalbuminuric 
diabetic patients.
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Discovery of the pathogenic process of the CNF has provided us with a deeper understanding of the 
molecular structure of the glomerular fi ltration diaphragm and knowledge that nephrin is a key molecule 
in the fi ltration function. The aims of this thesis are the following:
1.  To study the role of nephrin and lipid peroxidation in glomerular damage in the novel 
 hypercholesterolemic PAN mouse model (I)
2. To study the presence of urinary proteins, detected with nephrin antisera, in the urine of type 1  
 diabetic patients with or without nephropathy (II)
3. To identify nephrin among the proteins found in the urine of type 1 diabetic patients (III)
4. To study whether the 75 kDa urinary nephrin can be used as a marker for progression of diabetic 
 nephropathy in type 1 diabetes (III)
5.  To study whether offspring of type 2 diabetic patients exhibit urinary proteins detectable with 
 nephrin antiserum and whether presence of these proteins associate with mediators of glucose 
 metabolism, especially with insulin resistance (IV)
3. AIMS OF THE PRESENT STUDY
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4.1. Tissues
Normal kidney tissue was obtained from De-
partment of Surgery (University of Helsinki, 
Finland) from cadaver kidneys taken for trans-
plantation but not grafted because of vascular 
anatomic abnormalities in accordance with the 
principles of the Declaration of Helsinki. Kidney 
cortex was stored at –70°C, and the tissue was 
used as such or further prepared for glomerular 
isolation by graded sieving method (Holthofer et 
al., 1994; Striker and Striker, 1985). Collected 
glomeruli were aliquoted and stored in –70°C 
for lysate preparation (Study IV, Research design 
and methods).
4. MATERIALS AND METHODS 
4.2. Animals
The ApoE knockout mice were housed in con-
trolled humidity and temperature in the animal 
facility of University of Tampere, Finland. The 
procedures were approved by the ethics commit-
tee of the University of Tampere. The mice were 
randomly assigned to two main dietary groups: 
apoE group-1 fed with normal mouse chow diet, 
and apoE group-2 fed with a high fat diet. The 
mice were further divided into four treatment 
subgroups: puromycin, puromycin + probucol, 
probucol and control as shown in Table 4.1 (See 
details in Study I, Methods). The PAN was in-
duced by a single 15 mg/100 g intraperitoneal 
injection of puromycin (Sigma Chemicals Co, St 
Louis, MO, USA) and the control group received 
an equal volume of 0.9% saline. Probucol (Sigma 
Chemicals) was given in the diet (2% wt/wt) and 
consumption was recorded daily.
Table 4.1. Experimental design of Study I
Treatment
High fat diet (ApoE group-2) N -10 days 0 days 3 days 8 days

















Normal mouse diet (ApoE group-1) N -10 days 0 days 3 days 8 days
PAN 2 U, PAN U, B, K ✝
PAN+Pro 2 Pro U, PAN U, B, K ✝
Pro 2 Pro U, saline U, B, K ✝
Control 2 U, saline U, B, K ✝
PAN, aminonucleoside of puromycin; Pro, probucol; ✝, sacrifi ce; U, urine sample; B, blood sample; K, 
kidney sample
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4.3. Measurement of nephrin mRNA   
 expression
Cortical kidney RNA was isolated from the 
frozen mouse tissues using the single-step acid 
guanidium thiocyanate-phenol-chloroform pro-
cedure with Trizol® reagent (Life Technologies, 
Gibco BRL, Paisley, UK) according to manu-
facturer’s instructions. For removal of genomic 
DNA, the total RNA was incubated with Dnase 
I (Promega, Madison, WI, USA) together with 
Rnase inhibitor (Promega) for 30 min at 37°C. 
Using oligo dT15 primer (Roche Diagnostics 
GmbH, Mannheim, Germany) and Moloney-
Murine Leukemia Virus reverse transcriptase 
(Promega) RNA was transcribed into cDNA fol-
lowed by quantifi cation of nephrin expression by 
Taqman® Real-Time PCR ABI Prism® 7700 
Sequence Detector System (Perkin-Elmer Ap-
plied Biosystems, Norwalk, CT, USA). In this 
method, a probe (5’-ccctctctaaatgcacggccacca-3’) 
with a 5’-reporter dye FAM® (6-carboxy-fl uo-
rescein) and a 3’-quencher dye TAMRA (6-car-
boxy-tetramethylrhodamine), and a primer pair 
5’-atctccaagaccccaggtacaca-3’ (forward) and 
5’-agggtcagggcgctgat-3’ (reverse) were used for 
amplifi cation of mouse nephrin cDNA. Taq-
man Universal Master Mix was used in all PCR 
reactions. Finally, nephrin mRNA level of each 
mouse was compared to its respective GAPDH 
(glyceraldehydes-3-phosphate dehydrogenase; 
housekeeping gene) mRNA level. 
4.4. Type 1 diabetic patients and controls
The type 1 diabetic patients (n=159) of cross-sec-
tional cohort of Study II and Study III (Cohort 
I) were from the FinnDiane study (Department 
of Medicine, Division of Nephrology, Helsinki 
University Central Hospital and Folkhälsan Re-
search Centre, Biomedicum Helsinki, Finland). 
FinnDiane is an ongoing, multicenter, nation-
wide study that aims at characterizing 25% of 
the Finnish type 1 diabetic population. The type 
1 diabetic patients were divided into four groups 
according to AER-measurements: Normoalbu-
minuric (Normo in Study II, Normo-I in Study 
III, n=40), microalbuminuric (Micro, Micro-
I, n=41), macroalbuminuric (Macro, Macro-I, 
n=39) and new microalbuminuric (newMicro, 
newMicro-I, n=39) groups. The newMicro con-
sisted of patients previously normoalbuminuric, 
but the urine sample analyzed in the study was 
the fi rst showing microalbuminuric range AER. 
The Macro patients had recent onset (<2 years) 
of diabetic nephropathy. Healthy nondiabetic 
laboratory personnel (n=29) were used as control 
subjects. For detailed clinical characteristics of 
the diabetic study subjects and healthy controls 
see Study II; Table 1, and Research design and 
methods. 
The Study III follow-up patients (Cohort 
II) were recruited from the Outpatient Clinic 
of the Department of Ophthalmology, Helsinki 
University Central Hospital, during years 1980-
1981. The patients were re-examined 7.8 years 
later. Research design and methods are described 
in detail in Study III. Every patient gave a written 
informed consent, and the studies were approved 
by the local ethics committees.
4.5. Offspring of type 2 diabetic patients and  
 controls
For Study IV 128 healthy offspring of type 2 
diabetic patients and 9 control subjects were 
studied. The diabetic patients (probands) were 
randomly selected among type 2 diabetic pa-
tients living in the region of Kuopio University 
Hospital. Spouses of the probands had to have 
a normal oral glucose tolerance test (OGTT). 
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One to three offspring from each family were in-
cluded in metabolic studies (details in Study IV; 
Research design and methods) of which OGTT, 
intravenous glucose tolerance test (IVGTT), 
and euglycemic hyperinsulinemic clamp (clamp) 
techniques are explained briefl y below. All study 
subjects gave written informed consent and the 
study was approved by the Ethics Committee of 
the University of Kuopio.
Table 4.2. Summary of subjects and urine samples in Studies II, III and IV
N Urine sample Classifi cation Used in
Type 1 diabetic patients, Cohort I 159 24-h urine AER II, III
Type 1 diabetic patients, 7.8-years follow up, 
Cohort II
73 24-h urine AER III
Offspring of type 2 diabetic patients 128 Timed overnight urine AER IV
Healthy control subjects, uncharacterized 29 Morning urine Alb/Crea II
Healthy control subjects, characterized by 
metabolic studies
9 Timed overnight urine AER IV
4.6. Oral glucose tolerance test (OGTT), 
 intravenous glucose tolerance test 
 (IVGTT) and euglycemic    
 hyperinsulinemic clamp  (clamp)
Glucose tolerance tests are used to determine the 
ability of an individual to maintain homeostasis 
of blood glucose. It includes measuring blood 
glucose levels in the fasting state and at prescribed 
intervals before and after oral glucose intake 
(OGTT) or intravenous infusion (intravenous 
glucose tolerance test, IVGTT). OGTT is widely 
used for detecting impaired glucose tolerance, i.e. 
a state with higher than normal blood glucose, 
but not high enough to establish a diagnosis of 
diabetes. After a 12-hours fast a 75 g glucose dose 
is given orally and samples for blood glucose and 
plasma insulin measurements are drawn at –10, 
0, 30, 60 and 120 min. For determining the fi rst-
phase insulin secretion capacity after a 12-hours 
fast an IVGTT is performed. In this method a 
bolus of glucose (300 mg/kg as a 50% solution) 
is given within 30 sec into the antecubital vein. 
Blood glucose and plasma insulin samples (arte-
rialized venous blood) are drawn at -5, 0, 2, 4, 6, 
8, 10, 20, 30, 40, 50 and 60 min. 
Insulin sensitivity can be evaluated with 
the euglycemic hyperinsulinemic clamp tech-
nique (clamp) using insulin infusion rate of 240 
pmol/min/m2 body surface area. Blood glucose 
for the next 120 min is maintained at 5.0 mmol/l 
by infusing 20% glucose at varying rates accord-
ing to blood glucose measurements performed at 
5-min intervals. Indirect calorimetry before the 
clamp and during the last 20 min of the clamp 
can be coupled to the technique using a compu-
terized fl ow-through canopy gas analyzer system 
(DELTATRAC®, TM Datex, Helsinki, Finland) 
(Vauhkonen et al., 1998). Mean values of the data 
during the last 20 min of the clamp are used to 
calculate the M-value (whole body glucose uptake; 
glucose infusion µmol/kg lean body mass/min), 
glucose oxidation and lipid oxidation. The rates 
of nonoxidative glucose disposal during the clamp 
may be estimated by subtracting the rates of glu-
cose oxidation from the glucose infusion rate. 
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4.7. Antibodies  used
Table 4.3.
Primary antibodies
Name Antigen Source Dilution or 
concentration
Used in
MDA (616) Mouse malondialdehyde Rabbit polyclonal, Dr. 
T. Montine (Mon-
tine et al., 1996)
IF 1:50 I
4-HNE (614) Mouse 4-hydroxynonenal Rabbit polyclonal, Dr. 
T. Montine (Mon-
tine et al., 1996)
IF1:50 I
Ant i -nephr in 
#6878
Mouse nephrin Rabbit polyclonal, Dr. 
L. Holzman (Holz-
man et al., 1999)
IF 1:100 I
Aff338 Human nephrin, recom-







Aff380 Human nephrin, recom-







#1188 Human nephrin, recom-
binant protein alpha-435: 
aa1031-1055 and 1096-1215
Rabbit polyclonal, protein 
A –purifi ed, rabbit 338
15 ug/ml III
#1135 Human nephrin, recom-
binant protein alpha-435: 
aa1031-1055 and 1096-1215
Rabbit polyclonal, protein 
A –purifi ed, rabbit 380
15 ug/ml III
Glucagon Human glucagon Rabbit polyclonal, Zymed IF 1:50 II
Secondary antibodies
Name Antigen Source Dilution Used in
FITC-anti Rb 
IgG










Rabbit IgG Goat polyclonal, HRP-
conjugated, Jackson
WB 1:40 000 II, III, 
IV
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4.8. Immunofl uorescence microscopy
Frozen (-70°C) kidney cortexes were embedded 
in Tissue-Tek® mounting medium (Sakura) and 
4-5 µm cryosections were cut. The sections were 
either fi xed with ice-cold (-20°C) acetone for 5 
min or air-dried for 30 min before fi xing with 
acetone. After washing with PBS the sections 
were incubated with primary antibody in 1% 
goat or 5% rat serum in PBS overnight at 6°C. 
The sections were washed with PBS followed by 
incubations with secondary antibody at room 
temperature for 30 min. The slides were covered 
with mounting medium (Shandon, Pittsburgh, 
PA, USA) and examined using an Olympus 
BX50 microscope (Olympus Optical, Tokyo, Ja-
pan) equipped with a CCD camera (Hamamatsu 
Photonics, Hamamatsu City, Japan). Openlab 
2.2.3 (Improvision, Coventry, U.K.) and Adobe 
Photoshop (Adobe Systems, San Jose, CA, USA) 
software was used for image documentation. For 
Study I a dilution series of the primary antibody 
was used to assess the level of nephrin protein 
expression. See details of the incubation and mi-
croscopy conditions in Study I (Methods) and 
Study II (Research design and methods).
4.9. Determination of urinary proteins
The mouse urinary albumin concentration was 
measured by nephelometry (Luimula et al., 
2000b). The human urine samples used and the 
methods for classifi cation of albumin excretion 
rate are listed in Table 4.2. Urinary albumin 
concentration was measured using radioimmu-
noassay in Study II. Alternatively, albumin was 
determined by immunoturbidometry (Study III) 
or by kinetic nephelometry (Study IV). 
Total urinary protein concentration was 
measured with the Lowry method using RC DC 
Protein Assay kit (Bio-Rad Laboratories, Hel-
cules, CA, USA) according to the manufacturer’s 
instructions. The concentration of non-albumin 
urinary proteins was calculated as the difference 
between the concentration of total protein mi-
nus the concentration of albumin. A larger urine 
volume corresponding to 30 µg of non-albumin 
proteins was used in Studies II and III. Because 
the albumin/total protein ratio of 42 samples in 
Study IV correlated with the ratios of Normo in 
Study II, we were able to calculate the total uri-
nary protein concentration for the rest of Study 
IV samples using the abovementioned formula 
and albumin concentration. 
4.10. Western blotting
Sample volumes corresponding to 30 µg of to-
tal protein or 30 µg of non-albumin proteins 
(microalbuminuric and macroalbuminuric 
groups in Studies II and III) were precipitated 
with 10% (wt/vol) trichloroacetic acid in PBS on 
ice for 30 min. The samples were centrifuged for 
10 min at 13,100g at 4°C and the precipitate was 
washed twice with ice-cold acetone. The samples 
were air-dried and dissolved in Laemmli buffer 
(62.5 mmol/l Tris-HCl (pH 6.8), 10% glycerol, 
2% SDS, 5% 2-mercaptoethanol, and 0.05% 
bromophenol blue) followed by heating at 95°C 
for 5 min. The samples were analyzed in 10% 
polyacrylamide gels with the Protean Mini-gel 
electrophoresis system using Ready Gels (Bio-
Rad Laboratories). A nephrinuric urine sample 
from a type 1 diabetic patient was used as a posi-
tive control in every gel. After the run the pro-
teins were transferred onto nitrocellulose fi lters 
(Amersham Biosciences, Buckinghamshire, UK) 
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followed by blocking for two hours at room tem-
perature (RT) with 3% non-fat dried milk (Val-
io, Helsinki, Finland) in PBS. The fi lters were 
incubated with the primary antibody (listed in 
Table 4.3) in PBS containing 1% non-fat dried 
milk and 0.02% sodium azide at RT (for 1 hour 
in Study II and III, and 1.5 hours in Study IV), 
and then washed several times in PBS containing 
0.2% Tween 20. Then the fi lters were incubated 
with horseradish peroxidase -labeled second-
ary antibody for one hour at RT, and washed as 
above. The bound antibody was detected with 
Super Signal ECL substrate (Pierce, Rockford, 
IL, USA). Presence of any protein band visible 
with both antibodies in Western blots was re-
garded as positive for nephrinuria in Study II. 
4.11. Absorption of antisera
The E. coli strain TOP10 (Invitrogen Life Tech-
nologies, Carlsbad, CA, USA) was used for pro-
duction of the alpha-435 recombinant fusion 
protein immunogen (Figure 2.4). A lysate of the 
nontransfected strain was produced as described 
in Study III. The primary polyclonal nephrin 
antiserum (5 ml of 15 µg/ml of IgG in PBS 
containing 1% non-fat dried milk and 0.02% 
sodium azide) was incubated with alpha-435 
antigen (100 µg and 600 µg) for four hours at 
RT to absorb the nephrin specifi c antibodies in 
the antiserum or alternatively with TOP10 lysate 
(100 µg and 600 µg) to absorb the E. coli specifi c 
antibodies. The absorbed antisera were then used 
as primary antibodies for Western blottings of 
the test samples (a positive urine sample from a 
nephrinuric type 1 diabetic patient and glomeru-
lar lysate) in Study III.
4.12. Statistical analyses 
Data were analyzed with BMDP statistical pack-
age (BMDP Statistical Software, Los Angeles, 
CA, USA) in Study II, and with the SPSS for 
Windows program (SPSS Inc., Chicago, IL, 
USA) in Studies III and IV. Differences between 
the groups were tested using analysis of variance 
(ANOVA). A P-value <0.05 was considered sta-
tistically signifi cant. Regression analysis was per-
formed to evaluate the association of different 
variables with whole body glucose uptake (M/I) 
in Study IV.
4.13. Miscellaneous
Serum cholesterol and triglyceride concentra-
tions were measured enzymatically in Study I 
(Friedewald et al., 1972). Routine clinical chem-
istry was performed in the central laboratories of 
Kuopio and Helsinki University Central Hospi-
tals in Studies II, III and IV.  
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5. RESULTS 
5.1. Hypercholesterolemia is a prerequisite  
 for glomerular damage in the    
 proteinuric PAN mouse model (I)
ApoE mice on a high fat diet (apoE group-2) 
had signifi cantly higher serum cholesterol val-
ues compared to the values of mice on a normal 
diet (Study I, Table 1). Interestingly, puromycin 
treated animals on high fat diet group had 34% 
lower cholesterol than control animals on same 
diet. Probucol lowered the cholesterol level alone 
and together with puromycin by 70%. Puromy-
cin was able to induce proteinuria in the apoE 
mice on a high fat diet, but not in apoE mice 
on a normal diet. The difference was most re-
markable at day 3 as shown in Figure 5.1 (see 
also Study I, Figure 1). Probucol treatment prior 
to puromycin injection was able to prevent pro-
teinuria. 
Figure 5.1 Urinary albumin-to-creatinine ratios of ApoE mice on high fat diet.
*p=0.05 P=Puromycin, Pro=Probucol
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5.2. Nephrin expression and lipid    
 peroxidation in hypercholesterolemic   
 PAN mouse model (I)
Nephrin mRNA expression decreased by 30% 
and 50% at days 3 and 8 after puromycin injec-
tion, respectively, but the changes were not sta-
tistically signifi cant (Study I, Figure 3). Probu-
col was able to increase nephrin expression both 
alone and when used with puromycin, although 
not statistically signifi cantly. At the protein level 
puromycin reduced nephrin expression in the 
glomeruli of apoE group-2 mice, but not when 
probucol was used prior to puromycin injection 
(Study I, Figure 4 and Table 2).
The immunostaining for MDA and 4-
HNE was increased at day 3 in puromycin-treat-
ed animals of apoE group-2 (Study I, Figure 2). 
In mice treated with probucol alone or probucol 
with puromycin, the staining was comparable to 
that of controls. The staining of MDA and 4-
HNE appeared to localize to the mesangial part 
of the glomeruli, although granular staining was 
also noticed next to the urinary space.
5.3. Urinary proteins detected by nephrin   
 antisera in type 1 diabetic patients with  
 or without nephropathy (II)
In Study II the criterion for nephrinuria was 
whether there was any protein band in urine that 
was visible with both of two different nephrin 
polyclonal antisera against the same immunogen 
alpha-435. Using this criterium, 30% of Normo 
patients were nephrinuric, while 28% of newMi-
cro and Macro patients. Of Micro patients 17% 
were nephrinuric, while all healthy control sub-
jects were negative (Study II, Figure 1). Of all 
female diabetic patients 35% but only 19% of 
all male patients were nephrinuric (P=0.02). Ne-
phrinuric and non-nephrinuric patients did not 
differ from each other in respect to the variables 
listed in Study II; Table 1. The nephrin antisera 
revealed protein bands in urine most commonly 
of sizes 32, 40, 60, and 75 kDa (Study II, Figure 
3). The antisera Aff338 and Aff380 also recog-
nized full-length nephrin (185kDa) in human 
glomerular lysate (Study II, Figure 3) and pro-
duced typical immunostaining of nephrin in hu-
man glomeruli (Study II, Figure 4).
5.4. Specifi city of the urinary proteins found  
 in type 1 diabetic patients (III)
To investigate which of the urinary proteins 
found in the urine of T1DM patient would be 
most specifi c for nephrin a specifi city assay was 
conducted with absorbed antibodies. In the 75 
kDa area a distinct and closely packed doublet of 
protein bands was detected and this doublet was 
called 75 kDa nephrin. 32 and 40 kDa bands 
weakened when the polyclonal nephrin antise-
rum was absorbed with TOP10 E. coli lysate 
suggesting that these band were not nephrin-de-
rived (Study III, Figure 1). However, both the 75 
kDa urinary nephrin and 185 kDa glomerular 
nephrin remained positive with this absorbed 
antibody, and disappeared when the antibody 
was absorbed with the immunogen, alpha-435 
(Study III, Figure 1). 
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5.5. The occurrence of 75 kDa nephrin is  
 highest in normoalbuminuric type 1 
 diabetic patients and diminishes when   
 diabetic nephropathy progresses (III)
According to the results of the specifi city assay 
using absorbed antibodies the 75 kDa protein 
was nephrin-derived. We reanalyzed the type 1 
diabetic patients of Study II, called the Cohort 
I in Study III, for the presence of this particular 
protein. The analysis revealed that of Normo-
I, newMicro-I, Micro-I, and Macro-I 22.5%, 
23.1%, 9.8%, and 2.6% (p=0.022), respectively, 
were positive (Study III, Figure 2). There were no 
signifi cant differences in clinical variables such as 
duration of diabetes, BMI, systolic blood pres-
sure, diastolic blood pressure, serum lipid levels 
or glycated hemoglobin levels between subjects 
positive or negative for 75 kDa nephrin. Of all 
diabetic female patients in Cohort I, 21.7% were 
nephrinuric compared with only 8.9% of the 
male patients (p=0.022). In Cohort II 75 kDa 
nephrin occurred in 45.4%, 26.4%, and 0% 
(p=0.001) in Normo-II, Micro-II and Macro-II 
groups, respectively (Study III, Figure 3). Pa-
tients positive or negative for 75 kDa nephrin 
did not differ signifi cantly from each other with 
respect to age, sex, duration of diabetes, BMI, 
serum lipid levels, serum creatinine, creatinine 
clearance or glycated hemoglobin. In total, four 
patients in the Normo-II group and six patients 
in the Micro-II group progressed. Of these pro-
gressors only two out of ten were positive for 75 
kDa nephrin at baseline while this was the case 
in 15 out of 36 nonprogressors (p=0.282; Study 
III, Figure 4). 
5.6. Offspring of type 2 diabetic patients   
 exhibit urinary proteins detectable with  
 a nephrin antiserum (IV)
Of all offspring 26.6% showed a 100 kDa uri-
nary protein in the Western blots that stained 
with the Aff338 antiserum (Study IV, Figure 1), 
while all control subjects were negative. The sub-
jects were divided into strongly positive (12.5%), 
weakly positive (14.1%) and negative groups and 
compared for the clinical characteristics. The 
offspring had lower HDL cholesterol than the 
healthy controls (Study IV, Table 1). The strongly 
positive offspring showed a trend towards lower 
HDL cholesterol, higher BMI, higher percentage 
of smokers, and higher fasting and 120 minutes 
insulin levels in OGTT, although these differenc-
es were not statistically signifi cant. Interestingly, 
the nephrin antiserum occasionally detected a 
100 kDa protein in glomerular lysate. Altogether 
79% of offspring and 78% of control subjects 
showed a urinary protein band of size 185-200 
kDa (Study IV, Figure 1). Subjects positive or 
negative for this band did not differ with respect 
to clinical and biochemical characteristics. 
5.7. The 100 kDa urinary protein is   
 associated with insulin resistance in the  
 offspring of type 2 diabetic patients (IV) 
During the fi rst 10 min of the intravenous glu-
cose tolerance test the strongly positive group 
had a higher insulin AUC value than the negative 
group (3700 ± 706 vs. 2306 ± 159 pmol/lxmin, 
P=0.007), but the insulin AUC of the weakly 
positive group (2456 ± 345 pmol/lxmin) did not 
differ signifi cantly from those of the other groups 
(Study IV, Figure 2). During the last 20 min of 
the euglycemic hyperinsulinemic clamp the in-
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sulin levels of the strongly positive offspring 
were higher compared to the levels of negative 
offspring (459.6 ± 29.9 pmol/l vs. 389.4 ± 8.3 
pmol/l, P=0.003) and tended to be higher than 
the levels of weakly positive offspring (427.8 ± 
17.2 pmol/l). The strongly positive offspring had 
lower insulin sensitivity than the negative off-
spring (11.3 ± 1.2 vs. 15.8 ± 0.6 µmol/kg/min/
pmol/l, P=0.007) as expressed by whole body glu-
cose uptake (M/I) normalized to plasma insulin 
concentrations during the last 20 minutes of the 
euglycemic hyperinsulinemic clamp (Study IV, 
Figure 3). After adjustment for the insulin AUC 
values during the fi rst 10 minutes of the IVGTT 
(ANCOVA) the difference in M/I between the 
groups disappeared suggesting that the subjects 
positive for the 100 kDa urinary protein were ca-
pable of compensating their insulin resistance by 
increased insulin secretion. Nonoxidative glucose 
disposal was lower in the strongly positive group 
compared to the negative group (6.4 ± 0.9 vs. 
10 ± 0.5 µmol/kg/min/pmol/l, P=0.007) but did 
not differ signifi cantly from that of the weakly 
positive group (9 ± 1.3 µmol/kg/min/pmol/l). 
Multiple regression analysis showed that the 
presence of 100 kDa urinary protein was associ-
ated with the rates of M/I and non-oxidative glu-
cose disposal independently of several factors as-
sociated with insulin resistance (Study IV, Table 
2). Subjects positive or negative for the 185-200 
kDa urinary protein did not show any difference 
in fi rst phase insulin secretion during IVGTT or 
in insulin sensitivity during the clamp.
37
6. DISCUSSION
6.1. Proteinuria, lipid peroxidation, and   
 nephrin expression in the PAN model of  
 hypercholesterolemic ApoE mice
The rat proteinuric PAN model has been widely 
used to mimic human minimal change disease, 
while mice are rather resistant to puromycin and 
have generally not shown proteinuria. In Study 
I only ApoE mice on a high fat diet with overt 
hypercholesterolemia were prone to puromy-
cin-induced proteinuria. Probucol reduced both 
cholesterolemia and proteinuria suggesting that 
hypercholesterolemia, actually, may act as a risk 
factor for proteinuria, rather than being a conse-
quence of kidney failure. In humans hypercho-
lesterolemia is a frequent fi nding in glomerular 
diseases (Kaysen et al., 1986; Keane et al., 1988), 
like in DN (Groop et al., 1996) although the 
mechanisms for this remain obscure. Microalbu-
minuric diabetic patients already show lipid ab-
normalities (Tarnow et al., 1996) and this is also 
the case in patients with the metabolic syndrome 
(Eckel et al., 2005). It is also known that with 
age ApoE-KO mice develop mild progressive re-
nal injury with spontaneous glomerular lesions 
with foam cells and widening of the mesangial 
area resembling changes in human type III hy-
perlipoproteinemia (Wen et al., 2002).
Lipid peroxidation is directly associated 
with glomerular damage as shown in the Hey-
mann nephritis model of membranous glomeru-
lonephritis (Neale et al., 1994; Neale et al., 1993) 
and in the PAN model (Gwinner et al., 1997). 
Puromycin may mediate its functions through 
mitochondrial damage (Goldenberg et al., 2005; 
Solin et al., 2000) or through production of ROS 
via the xanthine oxidase pathway (Diamond et 
al., 1986). Adenosine deaminase may also be in-
volved in this pathway by regulating production 
of ROS, since inhibition of adenosine deaminase 
prevents proteinuria in rat PAN (Nosaka et al., 
1997). However, the mechanisms by which ROS 
and particularly lipid peroxidation may cause 
renal disease remain to be defi ned. When ROS 
react with lipids, various adducts are formed, of 
which MDA and 4-HNE are some of the most 
abundant ones. MDA reacts with DNA and 
is mutagenic (Marnett, 2002), while 4-HNE 
stimulates neutrophil chemotaxis and activates 
enzymes like phospholipase C leading to altered 
cellular functions (Dianzani, 2003). Probucol 
is a lipid antioxidant and it has also previously 
been shown to lower lipoprotein levels and pro-
teinuria in PAN (Hirano et al., 1991). In Study 
I we found that puromycin-treated hypercholes-
terolemic mice showed increased levels of MDA 
and 4-HNE in the glomeruli, especially in the 
mesangial area. When given before puromycin, 
probucol prevented these changes. Taken to-
gether, these results suggest that high cholesterol, 
formation of ROS, and lipid peroxidation con-
tribute to the development of proteinuria.
In our study glomerular nephrin mRNA 
expression was diminished in hypercholeste-
rolemic mice by 30% and 50% at days 3 and 8 
after puromycin injection, respectively. The pro-
tein expression of nephrin was also diminished in 
proteinuric mice. Probucol reduced proteinuria 
and nephrin expression to the level of the control 
mice. These results are consistent with previous 
studies using the PAN model, in which nephrin 
staining also was reported to change from a linear 
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to more granular pattern (Kawachi et al., 2000; 
Luimula et al., 2000b). Using immuno-EM Lu-
imula et al. observed that nephrin shifted from 
slits to an apical position on podocytes. Similar 
results were observed in another study, but ne-
phrin expression was altered only in areas with 
foot process effacement, while in preserved areas 
the localization of nephrin was normal (Lee et al., 
2004). Kawachi et al. reported that podocin ex-
pression is also diminished in PAN but it did not 
shift to an apical localization but partly remained 
in the slit area in newly formed tight junctions. 
Furthermore, they suggested that podocin was 
excreted into urine (Kawachi et al., 2003). Po-
docin and podocalyxin have been found being 
excreted in urinary exosomes (Knepper, 2004). 
It has also been shown that podocyte loss and 
glomerulosclerosis are associated in the PAN 
model (Kim et al., 2001). At the same time po-
docytes appear in urine as evidenced by detec-
tion of nephrin mRNA (Kim et al., 2001). In-
terestingly, foot process effacement is preceded 
by induction of α-actinin and α3β1 integrin 
mRNA in PAN, suggesting that morphological 
changes i.e., alterations in podocyte proteins and 
disturbed interaction of proteins with GBM and 
with the actin cytoskeleton may lead to proteinu-
ria (Luimula et al., 2002; Smoyer et al., 1997). 
Puromycin caused a change to granular distribu-
tion of nephrin, podocin, and actin fi bers in a 
human podocyte cell line (Saleem et al., 2002). 
This effect was similar to that of cytochalasin, 
an agent that disrupts actin stress fi bers (Saleem 
et al., 2002). Changes in nephrin expression in 
PAN may thus be secondary to alterations in the 
actin cytoskeleton leading to disturbed podo-
cyte morphology. B7-1 (CD80) is not expressed 
in the normal podocyte, but its mRNA is up-
regulated in puromycin-treated podocytes. This 
was suggested to contribute to the pathogenesis 
of proteinuria by disrupting the slit diaphragm 
protein complex and by reorganizing the actin 
cytoskeleton (Reiser et al., 2004).
Megalin is a protein located between the 
podocyte and the GBM. It belongs to the LDL 
receptor family and could mediate some of the 
effects of hypercholesterolemia by acting as an 
endocytic receptor for lipoproteins (Kerjaschki et 
al., 1997). Some of the effects of hypercholester-
olemia could also be mediated through the RAS, 
since hypercholesterolemia increases angiotensin 
II type 1 receptors in vascular smooth muscle 
cells leading to an increase in ROS (Griendling 
et al., 1994; Nickenig et al., 1997). Blocking the 
RAS with ACE inhibitors or angiotensin-recep-
tor antagonists reduces proteinuria (Lewis et al., 
1993; Lewis et al., 2001; Parving et al., 2001). 
These agents also normalized changes in nephrin 
expression in a proteinuric model of Heymann 
nephritis (Benigni et al., 2001). Interestingly, 
ACE inhibitors have benefi cial effects even in 
the treatment of some CNF patients (Guez et 
al., 1998; Pomeranz et al., 1995). Hydroxy-3-
methylglutaryl coenzyme A reductase inhibitors, 
i.e. statins, are effective lipid lowering drugs and 
statin treatment protects kidneys from ischemia-
reperfusion injury in a uninephrectomized rat 
model (Gueler et al., 2002). The effects are pos-
sibly mediated through the nuclear factor-κB 
pathway (Gueler et al., 2002), which also medi-
ates angiotensin II signaling (Ruiz-Ortega et al., 
2000). Taken together, the results suggest a direct 
but as yet unknown relationship between serum 
lipids and proteinuria. Interestingly, induction 
of diabetes with streptozotocin in the ApoE-KO 
mice resulted in accelerated renal injury (Lassila 
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et al., 2004). The increase in albuminuria was at-
tenuated by treatment with an inhibitor of AGE 
formation and with a cross-link breaker that 
cleaves the preformed AGE (Lassila et al., 2004). 
The study suggested that AGE is not only de-
rived from glucose-dependent pathways but that 
lipids may also contribute to the accumulation 
of AGE. Attenuation of renal injury by AGE in-
hibitors was associated with reduced expression 
of profi brotic and proinfl ammatory substances 
like TGF-β1 and collagens (Lassila et al., 2004). 
6.2. Podocyturia, nephrin, and nephrinuria  
 in type 1 diabetes
The number of podocytes appears to be reduced 
in both T1DM (Steffes et al., 2001) and T2DM 
(Dalla Vestra et al., 2003; Pagtalunan et al., 1997). 
A study of T2DM patients showed that together 
with GBM thickening the podocyte foot proc-
esses were broadened, the podocyte number was 
reduced and the fi ltration surface area covered by 
remaining podocytes was increased (Pagtalunan 
et al., 1997). It has been shown that approxi-
mately one in fi ve podocytes is reduced in T1DM 
of short duration indicating an increased risk for 
functional abnormalities as diabetes progresses 
(Steffes et al., 2001). In another study on T1DM 
patients no changes in podocyte number were 
detected compared to healthy controls, but dur-
ing follow-up there was an association between 
podocyte loss and increased AER (White et al., 
2002). In T2DM patients a reduced number 
of podocytes predicts rapid progression of renal 
disease (Meyer et al., 1999) and an increase in 
AER (Dalla Vestra et al., 2003). It is believed that 
podocytes are incapable of replication and have 
a limited potential for repair (Kriz et al., 1998). 
Interestingly, viable detached podocytes have 
been found in urine of proteinuric rats (Peter-
mann et al., 2003) and patients with glomerular 
disease (Vogelmann et al., 2003). In the study 
by Vogelmann et al, the patients had focal seg-
mental glomerulosclerosis and Lupus nephritis, 
and over 80% of these patients had podocalyxin-
positive cells, regarded as podocytes, in the urine 
(Vogelmann et al., 2003). Interestingly, 44% of 
healthy controls also had podocyturia. Podoca-
lyxin is also expressed in human peripheral blood 
leucocytes at the mRNA, but not on the protein 
level (Kerosuo et al., 2004). Thus there is a pos-
sibility that podocalyxin-expressing cells in urine 
are not podocytes. Indeed in Vogelmann’s study, 
only 30-40% of the samples positive for podo-
calyxin were positive for other podocyte mark-
ers, such as synaptopodin, GLEPP1, or podocin. 
Part of the cells were apoptotic and podocyturia 
tended to be highest in patients with the lowest 
levels of albuminuria (Vogelmann et al., 2003). 
Podocalyxin was also used as a marker for urinary 
podocytes in a study of T2DM patients: 53% 
and 80% of microalbuminuric and macroalbu-
minuric patients, respectively, showed podocytu-
ria, whereas none of the controls or normoalbu-
minuric patients did (Nakamura et al., 2000b). 
That study found no correlation between AER 
and the number of urinary podocytes, and pa-
tients with chronic renal failure failed to show 
podocyturia. Interestingly, here an ACE inhibi-
tor, trandolapril, was able to reduce podocyturia 
in T2DM patients during 2-months follow-up 
(Nakamura et al., 2000b). In another study 21% 
of microalbuminuric T2DM patients showed po-
docyturia, and when these patients were treated 
with an antiplatelet drug dilazep dihydrochloride 
for six months their AER and also the number of 
podocytes in the urine decreased (Nakamura et 
40
al., 2000a). In lupus nephritis, podocyturia has 
been found in the active phase of the disease in 
patients showing proteinuria of over 500 mg/24 
h (Nakamura et al., 2000c). Here, patients with 
stable kidney function and healthy controls did 
not show any podocalyxin-positive cells in the 
urine. 
Altered nephrin expression in diabetes was 
fi rst demonstrated by Aaltonen et al. using ex-
perimental streptozotocin rat model (Aaltonen et 
al., 2001). Nephrin mRNA was increased at 4 
weeks after induction of diabetes and the same 
initial increase was also found in non-obese dia-
betic mice. Increase in nephrin expression in 
the pre-proteinuric stage has also been observed 
in the PAN model (Hosoyamada et al., 2005). 
When proteinuria progresses, nephrin expression 
has been found to be reduced both at the mRNA 
and protein level in experimental (Forbes, 2002; 
Kelly et al., 2002) and human studies (Doubli-
er et al., 2003; Koop et al., 2003). One study 
showed that expression of extracellular nephrin 
was diminished in DN but intracellular expres-
sion remained comparable to that of controls, 
although the intracellular expression was dimin-
ished in sclerotic areas (Benigni et al., 2004). It 
has been shown that the lower the numbers of 
nephrin positive cells (Toyoda et al., 2004) and 
the lower the level of nephrin mRNA expression 
are (Langham et al., 2002) in the glomeruli, the 
higher the level of urinary AER is.
One third of T1DM patients in Study II 
showed urinary proteins that reacted with ne-
phrin antisera. The criterion for nephrinuria in 
Study II was the presence of any protein band 
detectable with both antisera in Western blots. 
The most common protein sizes found were 
32, 40 and 75 kDa. When the patients with 
nephrinuria were compared to patients without 
nephrinuria no differences were found in clini-
cal characteristics, such as duration of diabetes, 
body mass index, blood pressure, use of RAS 
modifying drugs, smoking, AER, glycated he-
moglobin and cholesterol levels (Study II). Study 
III showed that of the urinary proteins reacting 
with nephrin antisera the 75 kDa protein most 
probably represents a nephrin fragment. In Study 
III the same patients as in Study II (Cohort I) 
and another T1DM patient cohort with or with-
out nephropathy (Cohort II) were analyzed for 
the presence of the 75 kDa urinary nephrin. In 
both cohorts 75 kDa nephrin was found most 
commonly in the normoalbuminuric and micro-
albuminuric patients, but it was not detectable 
in urine of healthy controls. This suggests that 
75 kDa nephrin is found specifi cally in T1DM 
and that its expression ceases when nephropathy 
progresses and proteinuria increases. In Cohort 
I most of the nephrinuric patients were female, 
but we did not fi nd any signifi cant differences 
in clinical variables between patients positive or 
negative for 75 kDa nephrin in the two cohorts.
A splicing variant of nephrin, nephrin α, 
has been found at the mRNA level in human 
(Holthofer et al., 1999) and rat glomeruli (Ahola 
et al., 1999). This form lacks the transmembrane 
region thus allowing production of a soluble 
form of the protein but the protein product has 
not yet been identifi ed. Both in Study II and III 
we did not fi nd full-length nephrin in the urine 
of T1DM patients. In the rat PAN model a 166 
kDa urinary nephrin has been found (Luimula et 
al., 2000a) (Aaltonen et al., 2001). In the stud-
ies of Aaltonen and of Luimula, an antiserum 
against the extracellular domain of nephrin was 
used. We used antisera against nephrin α and 
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these antisera have epitopes in the intra- and ex-
tracellular domains near the transmembrane re-
gion (unpublished results). It is possible that our 
antisera detected a degraded form of nephrin. 
Nephrin α has only been found at the mRNA 
level and a relatively short transcript of it has 
been demonstrated using primers spanning the 
transmembrane region of intact nephrin (Ahola 
et al., 1999; Holthofer et al., 1999), thus it is not 
known whether additional splicing occurs in its 
outermost extracellular part. The 75 kDa nephrin 
may represent the splicing variant of nephrin or 
a fragment of if. Podocytes may start to secrete 
or shed soluble nephrin or nephrin-like proteins 
as a physiological response to an altered glucose 
environment. It may also represent nephrin that 
had detached from podocytes and that was pro-
teolytically degraded during passage through 
the tubuli. Diabetes itself may cause metabolic 
changes and increase local proteolytic activity in 
the glomerulus leading to degradation of nephrin. 
Interestingly, proteolytic cleavage of urinary albu-
min has been observed in diabetic patients (Osi-
cka et al., 2000a). The 75 kDa nephrin may also 
represent a yet unidentifi ed nephrin-like protein. 
The fi nding that 75 kDa urinary nephrin was 
more common in normoalbuminuric patients 
compared to micro- and macroalbuminuric pa-
tients supports the fi nding that podocytes and/
or nephrin are excreted in the early phase of the 
disease in the same manner as in podocyturia. 
The 75 kDa nephrin may also derive from uri-
nary exosomes, as podocin and podocalyxin have 
been found in these (Knepper, 2002; Pisitkun et 
al., 2004). Interestingly, the nephrin-like protein 
NEPH2 is shed from podocytes by the action of 
a metalloproteinase, and it can be visualized with 
antibodies against the extracellular, but not the 
intracellular domain, suggesting that only the 
extracellular part is shed (Gerke et al., 2004). 
This form of the protein has also been found in 
urine of healthy subjects (Gerke et al., 2004). It 
is possible that the nephrin observed in our stud-
ies represent shed extracellular nephrin since our 
antisera do also recognize an epitope in the extra-
cellular part of nephrin near the transmembrane 
region (unpublished results). Interestingly, the 
32 and 40 kDa proteins lost positivity in West-
ern blotting when an antiserum absorbed with 
E. coli lysate was used. Polyclonal antisera raised 
against recombinant proteins produced in E. coli 
may react with bacterial proteins that contami-
nate the immunogen in spite of the purifi cation 
processes. When analyzing urine, contamination 
of the samples with E. coli is possible, since this 
bacterium belongs to the normal fl ora of the 
urinary tract. However, with antiserum that was 
absorbed with the E. coli lysate, the full-sized 
glomerular nephrin and the 75 kDa nephrin re-
mained reactive. These proteins became invisible 
when the nephrin immunogen alpha-435 was 
used for absorption, indicating that the antise-
rum detects nephrin.
What could be the mechanisms behind 
the changes in nephrin expression? An ACE 
inhibitor, perindopril, restores nephrin expres-
sion on human kidney biopsies in DN (Lang-
ham et al., 2002). It has also been shown that 
the AGE inhibitor aminoguanidine normalizes 
the decreased nephrin expression in a diabetic 
rat model (Davis et al., 2004), but in another 
study no effects on nephrin expression were ob-
served (Kelly et al., 2002). It is known that RAS 
modifi ers and aminoguanidine are able to reduce 
PKC activity in experimental diabetes (Osicka 
et al., 2000b) and that nephrin expression may 
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be modifi ed through this pathway (Wang et al., 
2001b). Furthermore, PKC knockout mice are 
protected against development of albuminuria in 
diabetes (Menne et al., 2004). The effect of RAS 
inhibition seems to be quite specifi c for nephrin 
expression, since calcium channel blockers were 
not able to restore nephrin expression whereas 
valsartan was (Davis et al., 2003a). Interestingly, 
vasoactive mechanisms other than angiotensin II 
may be important modulators of nephrin expres-
sion, since the vasopeptidase inhibitor omapat-
rilat was also able to restore nephrin expression 
in a diabetic rat model (Davis et al., 2003b). 
Vasopeptidase inhibitors simultaneously inhibit 
both ACE and neutral endopeptidase leading to 
decreased levels of vasoconstrictor effector mol-
ecules such as angiotensin II as well as an increase 
in the levels of vasodilatory agents such as atrial 
natriuretic peptide and bradykinin (Fournie-Za-
luski et al., 1994). Mechanical strain also causes 
up-regulation of angiotensin II and the produc-
tion of angiotensin II type 1 receptors in podo-
cyte culture, and valsartan ameliorates stretch-in-
duced apoptosis (Durvasula et al., 2004). In the 
same study added exogenous angiotensin II alone 
increased podocyte apoptosis. Over-expression of 
angiotensin II type 1 receptors in podocytes led 
to glomerulosclerosis in a transgenic rat model 
(Hoffmann et al., 2004). In our studies females 
showed more often nephrinuria than did males. 
The difference could be explained by the fact that 
androgens stimulate the systemic and local RAS 
(Kang and Miller, 2002) and this could lead to 
increased angiotensin II levels and then decreased 
expression of nephrin in diabetes. This could also 
be one cause for the male gender being a known 
risk factor for DN (Seliger et al., 2001). 
The occurrence of urinary 75 kDa nephrin 
was lower in T1DM patients with more severe 
nephropathy compared to that of normoalbu-
minuric and microalbuminuric patients in both 
patient cohorts in Study III. When proteinuria 
and DN progresses the expression of 75 kDa 
nephrin ceases. The patients of Cohort II were 
followed for 7.8 years for progression of DN. 
We analyzed the progression of patients that 
were normoalbuminuric or microalbuminuric 
at baseline, since the macroalbuminuric patients 
already had overt nephropathy and no patients 
were positive for 75 kDa nephrin in that group. 
These preliminary results showed that 20% of 
progressors were nephrinuric as compared to 
42% of non-progressors. It is conceivable that 
75 kDa nephrin is a marker of slower progres-
sion of diabetic nephropathy, but the fi nding was 
not statistically signifi cant and more patients are 
needed to answer this question. 
Nephrin is found in very low amounts in 
the pancreatic islets of Langerhans (Palmen et al., 
2001; Putaala et al., 2001). Beta cells (Palmen et 
al., 2001) and islet microendothelia (Zanone et 
al., 2005) are proposed to exhibit specifi c expres-
sion. The function of pancreatic nephrin is still 
not known, but it does not appear to have any 
major signifi cance for insulin secretion as studied 
in CNF patients using OGTT (Kuusniemi et al., 
2004). Circulating antibodies against nephrin 
have been found in a subset of T1DM patients 
(Aaltonen et al., 2003). In experimental models 
injection of nephrin antibodies caused massive 
proteinuria in rats (Orikasa et al., 1988) and 
decreased nephrin expression (Kawachi et al., 
2000). Interestingly, some CNF patients show 
increased nephrin autoantibody titers during 
recurrence of nephrotic syndrome after trans-
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plantation (Patrakka et al., 2002b; Wang et al., 
2001a). It remains to be studied whether nephrin 
autoantibodies have real pathophysiologic im-
portance for the development of DN.
6.3. Nephrin and insulin resistance
In Study IV we found a 100 kDa urinary pro-
tein that reacted with a nephrin antiserum in the 
urine of approximately one third of the offspring 
of T2DM patients. Healthy controls that did 
not have any fi rst-degree relative with T2DM 
were all negative for this protein. The offspring 
of T2DM patients have an almost threefold 
increased risk of diabetes in comparison to the 
background population and insulin resistance is 
an early metabolic feature of the offspring (Eriks-
son et al., 1989). Thus even though the study 
subjects were relatively healthy and young they 
could be considered somewhat abnormal regard-
ing their glucose and insulin metabolism. Thus it 
is interesting that they showed changes in urinary 
excretion of the 100 kDa nephrin. The strongly 
positive subjects were more insulin resistant than 
weakly positive and negative ones. We did not 
fi nd any difference between the positive and 
negative groups with respect to AER. Generally, 
microalbuminuria is considered a characteristic 
of the metabolic syndrome (Haffner et al., 1993). 
However, microalbuminuria has (Nosadini et al., 
1992) (Forsblom et al., 1995) and has not (Toft 
et al., 2002) been associated with insulin resist-
ance. 
There are no studies concerning insulin re-
sistance and the presence of podocyte proteins in 
urine but one study showed that piogliotazone 
was able to reduce both AER and the number 
of urinary podocytes in T2DM patients (Naka-
mura et al., 2001). Piogliotazone is an insulin-
sensitizing agent that reduces insulin resistance 
by activating the peroxisome proliferator acti-
vated receptor gamma (PPAR-gamma). This 
pathway could also alter nephrin expression. 
Doublier et al. found that angiotensin II caused 
rearrangement of the actin cytoskeleton and de-
creased nephrin expression in cultured podocytes 
(Doublier et al., 2003). This was accompanied 
by excretion of a 100 kDa protein reacting with 
a nephrin antibody against the extracellular do-
main but not with an antibody against the in-
tracellular domain (Doublier et al., 2003). It 
is possible that this protein represents the 100 
kDa nephrin found in the offspring of T2DM 
in Study IV, since the antiserum used also rec-
ognizes an epitope in the extracellular domain 
of nephrin. Doublier’s study also showed that 
glycated albumin caused a decrease in nephrin 
expression in podocytes and this was mediated 
through RAGE. When this pathway was active 
there was no excretion of the 100 kDa nephrin. 
RAS is involved in insulin resistance since RAS 
blockade increases adiponectin concentrations 
in patients with hypertension (Furuhashi et al., 
2003). Adiponectin is an adipocyte-derived pro-
tein that has been suggested to play an important 
role in insulin sensitivity (Furuhashi et al., 2003). 
Large intervention studies have shown that ACE 
inhibitors and angiotensin-receptor antagonists 
may prevent development of T2DM (Hansson 
et al., 1999; Julius et al., 2004; Lindholm et al., 
2002; Yusuf et al., 2000). The mechanisms caus-
ing insulin resistance may also affect podocytes. 
Insulin resistant diabetic Zucker rats show pro-
gressive diabetic nephropathy with evidence of 
podocyte injury and cultured podocytes exposed 
to high glucose show hypertrophy (Hoshi et al., 
2002). A genetic model of lipoatrophic diabetes 
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(A-ZIP/F-1 mice) also show DN that is associ-
ated with podocyte damage (Suganami et al., 
2005).
What could be the source of 100 kDa uri-
nary nephrin, and why do the offspring of T2DM 
patients show this protein and not 75kDa urinary 
nephrin? What could be the biological signifi -
cance of the 75 kDa and 100 kDa nephrins? The 
hypotheses proposed for the 75 kDa nephrin are 
valid also for the 100 kDa nephrin. The subjects 
in Study IV were healthy offspring of T2DM pa-
tients whereas the T1DM patients in Studies II 
and III had a long history of severely disturbed 
glucose metabolism causing pathophysiologic 
post-translational protein modifi cations, and al-
tered intracellular signaling pathways. It must be 
addressed that T2DM is a heterogeneous disease 
with different, yet unidentifi ed subgroups due to 
polygenic inheritance and environmental factors 
affecting the disease development and the pre-di-
abetic stage. This may explain why the results for 
T1DM patients differ from those for offspring 
of T2DM patients. Furthermore, in studies of 
T1DM patients a sample from 24-h urine col-
lection was used instead of timed overnight urine 
in Study IV for offspring of T2DM patients. The 
24-h urine sample may have been stored for a 
longer time at room temperature compared to the 
timed overnight urine sample that was collected 
and quickly frozen in the morning when the 
metabolic studies were conducted. Degradation 
during storage may have caused the difference in 
size of the nephrin fragments detected. This may 
also explain the fi nding that in Study IV a larger, 
185-200 kDa protein was observed in some sam-
ples. All the samples in Studies II-IV were frozen 
without centrifugation, preservatives or protein-
ase inhibitors. The nephrins may originate from 
cells or from the soluble fraction of urine. Fur-
ther identifi cation and characterization of the 
100 kDa and 75 kDa urinary nephrins will be 
particularly important. Interestingly, a 100 kDa 
form of nephrin was also detected in glomerular 
lysate in Study IV. To clarify the source of the 
nephrin fragments in urine the proteins need to 
be characterized by proteomic methods includ-
ing mass-spectrometry. Nephrin has been identi-
fi ed using mass-spectrometry in only one study, 
in which nephrin was purifi ed from 100 rat kid-
neys and identifi ed by sequencing three peptides 
(Topham et al., 1999). Thus the task is demand-
ing and characterization of the urinary nephrin 
fragments is the topic for further studies. 
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7. CONCLUSIONS 
Puromycin causes proteinuria in ApoE mice on 
a high fat diet with overt hypercholesterolemia, 
but not in ApoE mice on a normal mouse diet. 
Pretreatment with the lipid antioxidant probucol 
reduces serum cholesterol levels and proteinuria. 
The proteinuric mice show decreased expression 
of glomerular nephrin, which is accompanied by 
increased levels of lipid peroxidation adducts, 
MDA and 4-HNE. Probucol also normalized 
the expression of nephrin and lipid peroxida-
tion adducts. Taken together the results suggest 
a role for cholesterol and lipid peroxidation in 
proteinuria and in nephrin expression.
Approximately one third of type 1 diabetic 
patients with or without nephropathy showed 
urinary proteins detectable with nephrin antisera. 
Female patients more often showed nephrinuria 
than male patients. None of the control subjects 
showed nephrinuria. Of the urinary proteins re-
acting with nephrin antisera the 75 kDa protein 
appears to be nephrin-derived fragment. The oc-
currence of 75 kDa nephrin is highest in normo- 
and microalbuminuric type 1 diabetic patients 
and decreases when nephropathy progresses. 
20% of progressors and 42% or non-progressors 
were nephrinuric at baseline in 7.8 years follow-
up (p=0.282). Whether 75 kDa urinary nephrin 
has true prognostic value for diabetic nephropa-
thy requires further investigation with a larger 
number of patients.
Proteins detectable with nephrin antiserum 
are more often present in urine of offspring of 
type 2 diabetic patients than in that of controls. 
A 100 kDa nephrin fragment was associated with 
insulin resistance and with lower levels of non-
oxidative glucose disposal. Whether this protein 
may serve as a marker of susceptibility for type 2 
diabetes needs further investigation and follow-
up. 
It would be important to fi nd new urinary 
markers for insulin resistance and for the meta-
bolic syndrome that could be used for evaluating 
the risk of individuals to develop T2DM. Such 
markers would provide new information about 
the pathological processes causing diabetes and 
diabetic complications and they might also facili-
tate development of new drugs that could pre-
vent the adverse effects of diabetes.
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Nuoruustyypin ja erityisesti aikuistyypin sokeri-
tautia sairastavien potilaiden määrä lisääntyy ym-
päri maailman. Tämä kehitys aiheuttaa haasteita 
sokeritaudin ja sen liitännäissairauksien aikaiselle 
toteamiselle. Noin 20-30% sokeritautipotilaista 
kehittää taudin edetessä munuaisvaurion, yleisen 
liitännäissairauden, jonka toteamiseen käytetään 
virtsan tärkeimmän valkuaisen, albumiinin, mit-
tausta. Munuaisvaurion esivaiheessa albumiinia 
vuotaa pieniä määriä munaisen suodatuskalvon 
lävitse virtsaan ja tätä ilmiötä kutsutaan mikroal-
buminuriaksi. Mikroalbuminuriavaiheessa osal-
la sokeritautipotilaista on jo pysyviä muutoksia 
munuaisissaan. Nefriini on tärkeä munuaisen 
rakennevalkuaisaine ja se muodostaa keskeisen 
osan toiminnallisesta munuaisen suodatuskalvos-
ta. Kokeellisissa malleissa ja sokeritautipotilaiden 
munuaisnäytteissä on todettu nefriinin vähene-
vän sokeritaudin munuaisvaurion kehittyessä. 
Korkea veren kolesterolipitoisuus, hyper-
kolesterolemia, on tunnettu riskitekijä munu-
aisvaurion etenemiselle ja hyperkolesterolemia 
löytyy useimmilta munuaisvauriopotilaista. 
Aikuistyypin sokeritautipotilaiden lähisu-
kulaisten tiedetään olevan suuremmassa riskis-
sä sairastua sokeritautiin kuin muun väestön. 
Aikuistyypin sokeritaudin kehittymistä edeltää 
usein tila, jossa kudokset kuten lihakset ja ras-
vakudos eivät reagoikaan enää yhtä hyvin sokeri-
aineenvaihdunnassa tärkeälle hormonille, insulii-
nille. Tätä tilaa kutsutaan insuliiniresistenssiksi. 
Insuliini toimittaa veressä olevan sokerin kudos-
ten soluihin ja mikäli kudokset eivät enää reagoi 
sille veren sokeripitoisuus nousee. Aikuistyypin 
sokeritautipotilaiden lähisukulaisten, mm. las-
ten, tiedetään olevan insuliiniresistentimpejä 
kuin muun väestön.
8. YLEISTIETEELLINEN YHTEENVETO SUOMEKSI
Tutkimuksen tarkoituksena oli selvittää 
miten hyperkolesterolemia vaikuttaa munuais-
vaurion kehittymiseen käyttämällä kokeellista 
mallia, jossa munuaisvaurio saadaan aikaiseksi 
puromysiini-nimisellä aineella hiirillä, joilla on 
geneettisen muuntelun vuoksi normaalia kor-
keammat veren kolesteroliarvot. Tutkimuksessa 
mitattiin valkuaisvirtsaisuuden kehittymistä, 
nefriinin muutoksia munuaisissa, sekä rasvojen 
hapettumisen yhteydessä syntyviä yhdisteitä mu-
nuaisissa, sekä sitä, miten rasvojen hapettumista 
vähentävä aine, probukoli, vaikuttaa mallissa. 
Hiirille, joilla oli hyperkolesterolemia, kehittyi 
vaikeampi munuaisvaurio kuin hiirille, joilla oli 
alhaisemmat veren kolesterolitasot. Probukoli vä-
hensi veren kolesterolipitoisuutta ja lievensi myös 
munuaisvauriota. Mallissa havaittuun munuais-
vaurioon liittyi myös nefriinin vähentyminen 
sekä rasvojen hapettumisen yhteydessä syntyvien 
tuotteiden lisääntyminen munuaisessa.
Väitöstutkimuksessa selvitettiin edelleen 
löytyykö nuoruustyypin sokeritautipotilaiden 
virtsasta rakennevalkuaisaine nefriiniä tai sen pilk-
koutumistuotteita ja voidaanko virtsan nefriiniä 
pitää munuaisvaurion kehittymistä ennustavana 
merkkiaineena. Virtsanäyte tutkittiin  kahden 
tutkimuksen potilailta, joista osalla ei ollut vielä 
munuaisvauriota, osalla oli munuaisvaurion var-
haisvaihetta kuvaava mikroalbuminuria ja osalla 
jo merkittävä munuaisvaurio valkuaisvirtsaisuu-
della. Näistä potilaista noin kolmasosalta löytyi 
valkuaisaineita virtsasta, jotka oli osoitettavissa 
nefriiniin sitoutuvalla vasta-aineella. Jatkotutki-
muksessa kävi ilmi, että näistä valkuaisaineista 
75 kDa -kokoinen kappale edusti mitä todennä-
köisimmin nefriiniä tai nefriinin kaltaista valku-
47
aisainetta. Tämä valkuaisaine löytyi useimmiten 
sokeritautipotilailta, joilla ei ollut vielä merkkejä 
alkavasta tai varsinaisesta munuaisvauriosta, kun 
taas tämän valkuaisaineen esiintyvyys oli vähäi-
sempi, mikäli munuaisvaurio oli edennyt pitkäl-
le. Osa potilaista kuului seurantatutkimukseen, 
jossa osoittautui, että potilaat, joilta 75 kDa -
nefriini löytyi tutkimuksen alkuvaiheessa, eivät 
edenneet varsinaiseen munuaistautiin yhtä nope-
asti kuin ne, joiden virtsassa tätä valkuaisainetta 
ei ollut. 
Kolmantena tavoitteena oli selvittää löytyy-
kö nefriiniä tai sen kaltaista valkuaisainetta ai-
kuistyypin sokeritautipotilaiden lähisukulaisten 
virtsasta ja mikäli löytyy, liittyykö sen esiintymi-
nen jotenkin heidän sokeriaineenvaihduntansa 
muutoksiin. Kävi ilmi, että 27% lähisukulaisista 
löytyi virtsasta 100 kDa -kokoinen valkuaisaine, 
jota ei ollut terveiden kontrollihenkilöiden virt-
sassa. Ne, joilta kyseistä valkuaisainetta virtsasta 
löytyi, olivat insuliiniresistentimpejä kuin ne, 
joilta sitä ei löytynyt.
Korkea veren kolesterolipitoisuus, eli hy-
perkolesterolemia, on selvästi myös altistava 
tekijä munuaisvauriolle, eikä vain munuaisvau-
rion seuraus. Hyperkolesterolemian altistamaan 
munuaisvaurioon liittyy rasvojen hapettuminen 
ja nefriinin vähentyminen munuaisissa. 75 kDa 
-nefriini voi olla merkki nuoruustyypin sokeri-
tautipotilaan pienemmästä riskistä saada munu-
aisvaurio, mutta potilasaineiston koosta johtuen 
näitä tuloksia on pidettävä alustavina. Aikuistyy-
pin sokeritautipotilaiden lähisukulaisilta löytynyt 
100 kDa -nefriini voisi toimia insuliiniresistens-
sin merkkiaineena ja mahdollisesti myös ennus-
taa riskiä sairastua aikuistyypin sokeritautiin. On 
tärkeää löytää uusia merkkiaineita sokeritaudin 
varhaisvaiheen tunnistamiselle ja liitännäissaira-
uksien kehittymisen ennustamiselle, jotta näiden 
sairauksien kehittymistä estävät elintapamuu-
tokset ja/tai lääkitys voidaan aloittaa tehokkaasti 
mahdollisimman varhaisessa vaiheessa. Virtsan 
merkkiaineet tuovat uutta tietoa tautien ja nii-
den liitännäissairauksien kehittymisestä ja voivat 
siten auttaa jopa uusien lääkkeiden kehittämistä.
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